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 Abstract Rosamund May Paisey 
Exploring the Patient Experience of Changes in Appetite and 
Diet with Incretin Analogue Therapy  
 
Incretin analogue therapies are a valuable recent treatment option for type 2 
diabetes (T2D) as they can improve blood glucose control and aid weight loss. 
The way in which an individual recognises and responds to changes in satiety 
signals induced by these treatments may explain why individual response is 
variable. Purposive sampling of individuals with successful outcome of incretin 
analogue therapy (GLP-1) for T2D gathered a participant cohort 15 people with 
37 years (448 months) combined experience of this treatment and 149 years of 
living with diabetes. The focus group data reported in this thesis, explores their 
experiences, the differing relationship with food and varying strategies used to 
accommodate the incretin effect. The insightful contributions of living with T2D 
and integrating GLP-1 treatment into lifestyle will likely be applicable to a wider 
group, as the thoughts and experiences of the study participants should inform 
advice to people living with T2D considering GLP-1 treatment and those 
encountering difficulties after its introduction. The three broad themes which 
emerged from analysis: 1) The experience of ‘A Changed Relationship to Food 
and Eating’ set in context with links and interactions to both 2) ‘The Medical 
Experience’ and 3) ‘Social, Cultural and Emotional Influences’ are discussed in 
the context of existing evidence. The physical, social and emotional aspects of 
living with diabetes and the wider issues of how changed food and eating 
practices, have impacted on a generation and links with obesity and chronic 
disease risk are also explored.  
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Chapter 1 Introduction  
1.1 The Global, National and Local Impact of Diabetes 
Diabetes is a metabolic disorder of multiple aetiology, characterised by chronic 
hyperglycaemia leading to the diabetes specific microvascular complications of 
retinopathy, nephropathy and neuropathy. The additional disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action or both, contribute to an increased risk of 
macrovascular complications particularly ischaemic heart disease, stroke and 
peripheral vascular disease, all contributing to a diminished quality of life (WHO 
2012; The International Expert Committee 2009; Alberti and Zimmet 1998). As 
one of the commonest non-communicable, chronic diseases worldwide, 
diabetes is recognised as a major health and development challenge of the 21st 
century (Whiting et al 2011; Unwin et al 2010). The increased morbidity and 
mortality caused by diabetes has far reaching implications for healthcare costs, 
quality of life and life expectancy (Danaei et al 2011). The International 
Diabetes Federation (IDF 2012) highlights that in 2011 diabetes accounted for 
11% of total global healthcare spending in adults (20-79 years), the majority of 
cases and fastest growth is seen in type 2 diabetes (T2D) mainly in 40-59 age 
range (González et al 2009; Mulnier et al 2006). In Europe fifty five million 
people (8.4% of adults) are living with diabetes, this is expected to rise to 64 
million by 2030 and 552 million globally (IDF 2012). Analysis of the UK national 
diabetes audit in 2011, showed that diabetes accounted for an extra 22,200 
deaths in England and those living with diabetes had a 39.9% greater risk of 
dying compared to the general population (YHPHO 2012). 
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These global and national trends have been mirrored in the district general 
hospital (DGH) in the South West of England where I work as a diabetes 
research nurse. Numbers identified as living with diabetes have increased more 
than fivefold in 25 years from 2,500 known cases in 1986 to over 14,500 in 
2011. This global diabetes epidemic has been fuelled by increasing levels of 
obesity, as developing countries have urbanised and adopted increasingly 
sedentary lifestyles with rapid changes from traditional to westernised diets (Hu 
2011; Zimmet 2000). Whilst in developed countries, improved healthcare and 
increased longevity of an ageing population as well as escalating obesity levels, 
contribute an overall increase of people living with diabetes (Shaw et al 2010). 
1.2 Reducing the risk of diabetes and complications  
Prospective and epidemiological studies have demonstrated that being 
overweight or obese is the most important risk factor for developing T2D (Malik 
et al 2012; The NHS Information Centre 2011; Colditz et al 1995). Nolan (2011) 
asserts that consumption of high-calorie, high-fat foods and inadequate physical 
activity results in an accumulation of excess weight as intra-abdominal fat in 
genetically susceptible individuals. This central adiposity increases the risk of 
ischaemic heart disease, hypertension and stroke and also accounts for 80–
90% of all T2D cases (Wassink et al 2011; Finucane et al 2011a). Astrup and 
Finer (2000) proposed redefining T2D as ‘diabesity’ in recognition of the 
importance of addressing both diabetes and obesity in management and 
treatment plans, as the significant health risks of each condition intensify when 
co-presenting (Colagiuri 2010; Campbell 2009). Lifestyle and dietary advice to 
support weight loss, increase activity and improve quality of diet have been 
shown to delay progression to T2D in at risk individuals and improve outcomes 
in established diabetes (DPP Research Group 2009; Lindström et al 2008). 
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Dietary advice is seen as underpinning all diabetes treatments, Diabetes UK 
guidelines recommend weight management as the primary approach to improve 
glycaemic control and reduce cardiovascular complications (Mellor 2012; Dyson 
et al 2011). However, maintaining success of lifestyle interventions over a long 
term has been elusive (The Look AHEAD Research Group 2013; West 1973). 
The UK Prospective Diabetes Study (UKPDS) demonstrated the importance of 
initiating active treatment following initial dietary advice to prevent or delay 
onset of diabetes micro and macrovascular complications and improve quality 
of life. This long term prospective randomised controlled trial (RCT) 
demonstrated a statistically significant association between incidence of micro 
and macrovascular complications, which were reduced with each incremental 
reduction in hyperglycaemia and hypertension respectively (Stratton et al 2006, 
2000) as shown in table 1, appendix V. The diabetes specific microvascular 
complications are thought to result from damage by glycosylation of proteins, 
whilst macrovascular complications are almost certainly linked to hypertension 
and dyslipidaemia as well as hyperglycaemia (Stratton et al 2006; Colhoun 
2004; Adler et al 2000). Established treatment pathways recommend addition of 
metformin to diet and exercise with the later addition of sulphonylurea and 
either glitazone or insulin if hyperglycaemia is not adequately controlled (NICE 
2013; Czupryniak 2009). However, these interventions do not resolve the 
underlying obesity and with the exception of metformin, frequently lead to 
increased weight and risk of hypoglycaemia (Bailey and Day 2010; Phung et al 
2010). This weight increase and risk of hypoglycaemia with sulphonylurea and 
insulin treatments is known to cause psychological distress and physical 
problems for patients (Khunti and Davies 2010; Amiel et al 2008; Hermansen 
and Mortensen 2007). 
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1.3 A solution to the cycle of weight gain with intensive therapy? 
Research has shown that gut hormones known as incretins are crucial in both 
glucose control and appetite suppression after food. Glucagon like peptide-1 
(GLP-1) stimulates insulin secretion, lowers glucagon levels, induces satiety 
and delays gastric emptying in response to rising glucose levels thus reducing 
post prandial hyperglycaemia (Nauck 2009; Drucker 2001). As GLP-1 levels 
have been found to be reduced in the majority of individuals with T2D, 
replacement of the hormone became a research priority, with exenatide 
(exendin-4) being the first incretin based therapy to be licensed. Initial studies 
showed significant weight loss and improvement in blood glucose levels in 
obese individuals with T2D (Barnett et al 2007; DeFronzo et al 2005). These 
newer treatments offer hope that the cycle of intensifying therapy and weight 
gain could be avoided. However, audits of use in general prescription have 
shown only a 50 to 60% success in reducing body weight by 5% and HbA1c by 
1% (Ryder et al 2010). The key factor associated with good response may be 
the way in which individuals respond to this newly discovered satiety during 
meals. The research on which this thesis reports explores dietary changes and 
adaptations made by those succeeding with this therapy. It is notable that there 
is no firm evidence base as to how best to advise patients initiating this therapy 
as the early studies did not include dietary advice. 
1.3 The Research Idea 
Working as a research nurse in diabetes for 27 years I have had the privilege of 
recruiting over 1000 individuals into a variety of research studies. Some such as 
the UKPDS were long term from 1986-2002, others shorter, but each has 
afforded the opportunity not only to capture study data and clinical outcomes 
whilst providing care and support but also the luxury of time to listen to each 
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individual story. My initial research question for the study which I report here, 
emerged from clinical experience whilst working closely with a group of people 
living with T2D recruited as participants to a premarketing multicentre RCT the 
Helping Evaluate Exenatide versus Long Acting insulin (HEELA) study (Davies 
et al 2009). Exenatide (exendin-4) was the first incretin based therapy to be 
licensed for human use, therefore this group were amongst the first in the UK to 
use this class of medication. Although GLP-1 and agonists of it such as 
exenatide, had been shown to decrease energy intake, few of these initial 
studies included any investigation of particular individual dietary response 
(Edwards et al 2001; Verdich et al 2001; Flint et al 1998). There was 
consequently a paucity of evidence to support individuals with dietary advice 
starting this class of treatment either as part of the study or when available for 
wider prescription in the UK.  
Standard advice for people with T2D is to eat regular carbohydrates to prevent 
hypoglycaemia especially when escalating treatment dose or adding 
hypoglycaemic agents such as sulphonylurea or insulin (Diabetes UK 2012; 
Mellor 2012). This requirement to ensure regular carbohydrate portions or 
snacks tends to hinder attempts to stabilise or lose weight, thus weight gain is a 
frequent consequence, which may counteract any benefits of improved 
glycaemia (Phung et al 2010; Holman et al 2007). Hauber and colleagues 
(2009) found weight gain from medication and cardiovascular risk are significant 
predictors of likely medication non-adherence in T2D whilst Gelhorn and 
colleagues (2013) confirmed the importance of potential weight gain and risk of 
hypoglycaemia or gastrointestinal side effects negatively affecting medication 
preference and choice in participants surveyed. Individuals living with diabetes 
describe being frustrated, confused and feeling out of control when their weight 
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increases despite efforts to lose weight (Wallace and Mathews 2000). Fear of 
hypoglycaemia may also result in a pattern of increased carbohydrate snacks 
continuing even after changes in medication (Barendse 2012; Amiel et al 2008). 
Although studies demonstrated the potential for incretin based treatments to 
improve glycaemic control whilst also reducing weight, the lack of evidence to 
support dietary changes could be problematic. Healthcare professionals 
(HCP’s) with little experience of these newer treatments could assume 
carbohydrate snacks were necessary with any additional medication for 
diabetes and advise accordingly. This advice could negate the benefits of 
enhanced satiety and weight loss, whilst increasing the potential for 
gastrointestinal side effects. In my clinical experience of supporting participants 
in the HEELA Study (Davies et al 2009) I noted that those who successfully 
improved their glycaemic control and reduced weight reported spontaneously 
adapting their eating habits in response to the study medication. I discussed 
using this group of ‘expert patients’ experience to develop appropriate advice 
for clinicians and their patients with a variety of colleagues, and a research 
writing group, including a ‘patient representative’. All encouraged me to 
continue. 
1.4 The project 
I acquired charitable research funds for the project, university sponsorship and 
National Research Ethics Service (NRES) South West approval and my local 
hospital trust Research & Development (R&D) agreement. With relevant 
approvals in place, I felt as though I was embarking on a very exciting journey, 
as a nurse researcher leading my own project rather than a research nurse 
gathering data for others.  
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The acronym Eat study as a short title for- Experience of changes in Appetite 
and diet with incretin analogue Therapy –Exploring the ‘Patient Experience’ 
encapsulated the research idea. This was condensed during the writing of this 
thesis to ‘Exploring the ‘patient experience’ of changes in Appetite and diet with 
incretin analogue Therapy (EAT study)’. 
Qualitative research is frequently used to explore the personal or individual 
response to phenomena and to attempt to gain a deeper understanding of ‘the 
lived experience’ (Creswell 2009; Silverman 2004; Denzin and Lincoln 2000). 
As such a qualitative approach to study design and methodology was chosen 
as consistent with my study aims: 
•To explore how changes in appetite induced by incretin (satiety 
hormone) treatment of type 2 diabetes influences dietary choices. 
•To identify whether people treated with incretin analogue therapy 
develop strategies to moderate side effects. 
•To enable the 'lived experience' to inform clinical practice and 
patient education/advice. 
Purposeful sampling strategy was used to recruit participants with successful 
experience of incretin analogue therapy, by identifying individuals known from 
the previous research study and by referral from the clinical team. Fifteen 
participants with 3 - 52 months experience of incretin analogue therapy and 4 - 
22 years living with T2D were recruited to share their experience within a focus 
group. Data were collected during three focus groups each comprising five 
‘expert users’ between July and November 2011. Using focus groups facilitated 
access to a wide range of experiences, views and ideas shared in spontaneous 
and emotional way as well as insight into whether a consensus was (or was not) 
reached on the issues discussed (Minet et al 2011; Morgan 2010).  
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1.5 The thesis 
The subsequent chapters describe the research in more detail. Chapter 2 sets 
the context with references to a selection of relevant literature from a wide 
range of sources. Review of existing evidence was ongoing throughout the 
study, data analysis and writing of the thesis. Initial background reading focused 
on emerging clinical evidence establishing the safety and efficacy of the first of 
the incretin based treatments, exenatide. Although the side effect profile 
including reduced appetite with some nausea has been reported in clinical and 
basic science papers, there is a paucity of evidence examining the patient 
experience of the anorexigenic effects of treatment, thus endorsing a need for 
the study.  
Since the initial study proposal, clinical papers describing comparative efficacy 
and insights into the pathophysiology of diabetes have proliferated, as new 
GLP-1 based treatments have been marketed and licensed. A review of basic 
science and clinical papers enabled an understanding of the mode of action and 
impact for an individual living with established diabetes of GLP-1 treatment. A 
review of the evidence of the close relationship between increasing incidence of 
T2D and the global obesity epidemic demonstrated how these changes have 
impacted on a generation. Broadening the focus to include qualitative and 
quantitative papers across a wide range of disciplines illuminated the impact of 
these changes at a personal level within family and society. Insights relating to 
social and cultural attitudes to food and meals and living with diabetes have 
been gleaned from sociology and psychology literature and the healthcare 
disciplines of nursing, psychiatry and clinical psychology, dietetics and nutrition.  
In the methods and methodology chapter (C3) I position myself within the 
research through a biographical account of my interests and career path as 
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suggested by Swift and Tischler (2010) and Letherby (2013; 2004). I continue 
with the rationale for my choice of method, data collection and sampling 
strategy. The process of recruitment and consent including participants’ 
biographies, establishment of the groups and organisation of venue are 
described followed by a discussion of practical issues and reflections on my 
facilitation of the focus group and group dynamics. I present my approach to 
data analysis in the final section of chapter 3. 
In Chapter 4, I present my analysis of the data set within a framework of 
existing evidence and understanding, drawn from a range of academic 
disciplines. I use the three broad themes which emerged from analysis as titles 
for each subsection; the experience of ‘A Changed Relationship to Food and 
Eating’ set in context with links and interactions to both ‘The Medical 
Experience’ and ‘Social, Cultural and Emotional Influences’. Finally in chapter 5, 
I reflect on the process, outline the implications for future practice and suggest 
further avenues of enquiry. 
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Chapter 2 Background and Context 
2.1 Introduction  
In this chapter I describe the background to the research on which this thesis 
reports. The idea for the EAT study began when I was unable to find information 
to advise and support participants initiating GLP-1 analogue therapy as part of a 
clinical trial (Davies et al 2009). Clinical and basic science papers described 
side effects including reduced appetite and nausea, there was however a lack 
of evidence describing the individual experience of the anorexigenic effects of 
treatment in T2D, endorsing the value of a study (Verdich et al 2001; Naslund et 
al 1999). In keeping with the qualitative study design, wishing to approach the 
area with as few preconceptions as possible, I did not undertake a systematic 
review of the literature in advance. I attempted to set aside background 
knowledge from my clinical role whilst conducting focus groups, returning to a 
non-systematic review of existing and emerging clinical evidence as well as 
topics pertinent to issues identified within the focus groups and data analysis..  
The subsequent sections of this chapter present a review of basic science and 
clinical papers describing pathophysiology of T2D, pharmaceutical management 
and importance of diet and lifestyle advice to enable an understanding of mode 
of action of GLP-1 analogues and potential impact on established diabetes. A 
broader focus of qualitative and quantitative texts across a range of disciplines 
illuminates implications for an individual, their family and society of the 
increasing incidence of T2D and the global obesity epidemic. An exploration of 
the social and cultural attitudes to food and meals follows before returning the 
focus to the individual living with diabetes. 
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2.2 Physiology 
2.2.1 Diabetes diagnosis and classification  
The diagnostic criteria and aetiological classification of diabetes summarised in 
tables 2, 3 and 4 below have been hotly debated as described by Levy (2011). 
The diagnostic threshold levels of hyperglycaemia, have been chosen as they 
are accompanied by the appearance of the uniquely diabetic complications of 
retinopathy, neuropathy and nephropathy and a two to four fold increase in 
cardiovascular disease (American Diabetes Association 2012; Brunner et al 
2006). The use of glycosylated haemoglobin (HbA1c) to replace fasting plasma 
glucose and oral glucose tolerance tests was recommended as a more practical 
diagnostic tool for diabetes by an International Expert Committee (2009). 
Table 2 Diagnosis of diabetes recommendation HbA1c  
(The International Expert Committee 2009) 
A1C assay is an accurate, precise measure of chronic glycaemic levels and correlates 
well with the risk of diabetes complications. 
Diabetes diagnosed when HbA1C is ≥ 6.5% # confirmed with a repeat HbA1C test 
Previously recommended diagnostic methods are acceptable if HbA1C testing is not 
possible 
# International Federation of Clinical Chemistry ( IFCC ) equivalent 48 mmol /mol 
## Confirmation not required if symptomatic with plasma glucose levels > 11.1 mmol/l 
 
Table 3 Diagnostic criteria for diabetes using plasma glucose measurements 
 (WHO/IDF consultation 2006) 
 Fasting plasma 
glucose  
 
2 hour plasma 
glucose * 
Diabetes Type1 or Type 2 ≥7.0 mmol/l  Or *≥11.1 mmol/l 
Impaired Glucose Tolerance  <7.0 mmol/l  and 
*≥7.8 and <11.1 
mmol/l  
Impaired Fasting Glucose  
6.1 to 6.9 
mmol/l 
and (if 
measured) 
*<7.8 mmol/l  
* Venous plasma glucose 2 hours after ingestion of 75g oral glucose load  
Impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG) are 
recognised to be intermediate conditions reflecting an alteration from normal 
metabolism, indicating an increased risk of progression toward diabetes and a 
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proven increased risk of cardiovascular disease as highlighted by of the IDF 
Expert Consensus Workshop on IGT/IFG (2002). 
Table 4 Aetiological classification of disorders of glycaemia 
 (Zimmet et al 2001) 
Type 1 
beta-cell destruction, usually leading to absolute insulin deficiency 
Autoimmune Idiopathic 
Type 2 may range from predominantly insulin resistance with relative 
insulin deficiency to a predominantly secretory defect with or 
without insulin resistance 
Other 
specific 
types  
 
Genetic defects of beta-cell function 
Genetic defects in insulin action 
Diseases of the exocrine pancreas 
Endocrinopathies 
Drug- or chemical-induced 
Infections 
Uncommon forms of immune-mediated diabetes 
Other genetic syndromes sometimes associated with diabetes. 
American Diabetes Association  provide a fuller list of specific 
types (2012) 
Gestational 
diabetes 
Includes the former categories of gestational impaired glucose 
tolerance and gestational diabetes. 
As additional subtypes are discovered it is anticipated that they will be reclassified 
within their own specific category 
Less than 10% of diabetes cases globally are type 1 diabetes (T1D), in contrast 
over 90% are T2D characterised by resistance to the action of insulin and/or 
abnormal insulin secretion and disturbances of lipid metabolism (Nolan et al 
2011; González et al 2009; WHO/IDF consultation 2006).  
2.2.2 Pathophysiology of T2D 
The complex interaction of genetic, epigenetic, environmental and lifestyle 
factors leading to T2D is still not fully understood. There is widespread variation 
in susceptibility with some individuals and ethnic groups, particularly recently 
urbanised, developing cultures being at greater risk of T2D (Nolan et al 2011; 
Zimmet 2000). O’Rahilly (2011, 2009) highlights that research of single gene 
disorders, has led to better diagnosis and treatment for rare monogenic forms of 
diabetes and advanced understanding of hyperglycaemia and pathophysiology 
of diabetes. However, the association between increased incidence of T2D and 
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obesity, particularly central or visceral obesity and sedentary lifestyle is widely 
accepted, having been reported and studied in the past 50 years from 
Himsworth (1949) to the Nurses’ Health Study (Cameron et al 2013; Carey et al 
1997). 
Nolan and colleagues (2011) describe normal metabolism and the mechanisms 
that distinguish overweight or obese diabetes resistant individuals who remain 
healthy from those who develop diabetes. A compensatory increase in insulin 
secretion channels excess energy into subcutaneous fat, maintains healthy 
blood glucose and protects tissues and organs from the damaging effects of 
over nutrition. Whereas, in susceptible individuals a chronic energy imbalance 
overwhelms glucose homoeostasis and lipid trafficking, resulting in excess, 
hepatic, pancreatic beta cell and skeletal muscle intracellular fat. This disrupts 
the finely balanced interplay of hormonal responses to food, leading to a 
destructive cycle of glucotoxicity and lipotoxicity (DeFronzo 2009; Taylor 2008). 
Astrup and Finer (2000) proposed redefining T2D as ‘diabesity’ in recognition of 
the importance of addressing both diabetes and obesity in management and 
treatment plans, as the significant health risks of each condition intensify when 
co-presenting.  
Microvascular complications are seen as a consequence glycosylation from 
hyperglycaemia whilst dyslipidaemia as well as hyperglycaemia contributes to 
macrovascular complications. The UKPDS demonstrated a reduction of 
diabetes related deaths endpoints with improved glucose control (Stratton et al 
2000), appendix V table 5. Similarly, adequate blood pressure control in T2D 
reduced incidence of retinopathy and stroke (UKPDS Study Group 1998a, 
1998b). RCT’s of statin treatment for primary and secondary prevention of heart 
disease have shown a 30% reduction in cardiovascular morbidity and mortality 
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in 5 years (Ford et al 2007; Colhoun 2004; Collins 2003; Pedersen et al 2000). 
Targets to improve glucose control, reduce blood pressure and widespread use 
of statin treatment have been effective in improving life expectancy in T2D from 
10 to 20 years, thus prolonging exposure to hyperglycaemia and the associated 
risks of blindness, renal failure and lower limb amputation. This increased life 
expectancy coupled with increasing incidence of T2D at a progressively 
younger age makes expert management of diabetes to prevent or reduce 
complications more important (Fonseca 2009). 
2.2.3 Pharmaceutical management of T2D 
Convergence of evidence from studies such as the UKPDS for T2D (Stratton et 
al 2000; Manley et al 2000; UKPDS Study Group 1998c), the Diabetes Control 
and Complications Trial (DCCT) for T1D (DCCT Research Group 1994) and 
cardiovascular protection studies as cited, linked with a growing understanding 
of the physiology and genetics of diabetes has led to the adoption of an 
evidence based treatment pathway for T2D. Initial diet and lifestyle advice 
followed by a stepped escalation of treatment to achieve glycaemic targets is 
recommended due to the progressive nature of T2D with additional medications 
to reduce hypertension and cardiovascular risk factors (Matthews et al 1998). 
Despite being potentially burdensome for individuals and costly for health 
services, evidence of improved quality of life and cost effectiveness of reduced 
complications justify this polypharmacy (Gray 2000; UKPDS Study Group 
1999).  
The beneficial cardiovascular outcomes of metformin have led to its 
establishment as first line therapy for T2D (NICE 2013; Bailey 2008; UKPDS 
Study Group 1998c). Metformin does not induce hypoglycaemia, nor weight 
gain but may cause gastrointestinal side effects in 25% of patients leading to 
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10% discontinuation (Andújar-Plata et al 2012; Berne and Campbell 2011; 
Donnelly et al 2009a). In contrast, established second line treatments of 
sulphonylurea and insulin are associated with weight gain and hypoglycaemia 
(Morgan et al 2012; Phung et al 2010; Krentz 2005). Insulin action on 
intermediary metabolism and the pathophysiology of diabetes explain why this 
combination of therapies can increase appetite, causing weight increase and 
only partial restoration of the disordered lipid metabolism characteristic of T2D 
(Colagiuri 2010).  
During the past 15 years a parallel set of investigations has been undertaken 
flowing from the work of Bloom and Holst on gut hormones (Holst et al 2009; 
Flint et al 1998; Todd et al 1997). Over thirty separate peptide hormones are 
released from the gut to regulate appetite and satiety (De Silva and Bloom 
2012). Glucagon like peptide-1 (GLP-1) is released at the start of a meal, 
stimulating insulin secretion and lowering glucagon levels in response to rising 
glucose levels thus reducing post prandial hyperglycaemia. GLP-1 also induces 
satiety by direct effect on the hypothalamus and delays gastric emptying until 
degraded by the counter regulatory hormone DPP IV (Nauck 2009; Drucker 
2001). As GLP-1 levels have been found to be reduced in the majority of 
individuals with T2D replacement of the hormone became a research priority, 
with exenatide (exendin-4) being the first incretin based therapy to be licensed. 
However audits of use in general prescription have shown only a 50 to 60% 
success in reducing body weight by 5% and HbA1c by 1% (Ryder et al 2010). 
Possible behavioural reasons underlying the success/failure of these therapies 
are the subject of this research. 
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2.2.4 Diet and Lifestyle 
The key importance of diet and lifestyle in both the prevention of T2D (Gong 
2011; Diabetes Prevention Program Research Group 2009; Lindström et al 
2006) and management of established diabetes is internationally recognised 
(Andrews et al 2011; Dyson et al 2011). Dietary recommendations for diabetes 
have evolved over time, originally a low carbohydrate and high protein diet with 
strictly prescribed portions and carbohydrate exchanges developed for T1D 
(Lawrence 1933) was standard advice for all diabetes. During the 1980’s 
evidence of increased cardiovascular and renal disease in T2D led to 
recommendations to increase complex carbohydrate, fruit and vegetables, 
dietary fibre and to moderate protein intake and reduce saturated fat. This 
advice later merged with general healthy eating guidelines. Various specific 
dietetic approaches have been studied and highlighted in the media as ‘cures’ 
for diabetes including very low calorie meal replacement diets (VLCD), 
Mediterranean diet, Glycaemic Index (GI), low carbohydrate diet, intermittent 
fasting and bariatric surgery (Brown et al 2013; Santos et al 2012). The 
evidence that any of these approaches show long term benefit is poor (Day and 
Bailey 2012; Paisey et al 2002). The net effect for both the general public and 
many HCP’s is an uncertainty as to what a person with diabetes can and should 
eat, leading to a lack of consistent message from the health care team. Lawton 
(2005) suggests that recommendations based on existing healthy eating 
guidelines without specific person centred advice may undermine the value of 
the message and appear vague and non specific. Diabetes UK emphasise the 
importance of a multidisciplinary team led by a specialist registered dietitian to 
provide advice ‘tailored for the individual, taking into account personal and 
cultural preferences, beliefs, lifestyle and willingness and ability to change’ 
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(Dyson et al 2011, pp.1282–3). Krebs and Parry-Strong (2013) echo this when 
they suggest that the optimal diet for T2D is one that works for the individual. 
The pathway for managing T2D as published by NICE (2013) recommends 
structured education at or near to diagnosis with annual reinforcement and 
regular nutritional advice. Various diabetes educational programmes to provide 
advice and support have been developed and evaluated in the last 20 years 
(Trento and Porta 2012; Norris et al 2001; Kronsbein 1988). Provision of 
education has been variable and where it is available not always accessed by 
individuals with diabetes, Davies (2008) reports 70% uptake for the Diabetes 
Education and Self Management Ongoing and Newly Diagnosed (Desmond) 
study whilst in the X-Pert patient study 21.8% of those approached responded 
to an invitation to join (Deakin et al 2006). However, the Diabetes Attitude, 
Wishes and Needs second study (DAWN2) found that cross-nationally 81% of 
people with diabetes who attended education programmes found them 
somewhat or very helpful (Nicolucci et al 2013).  
2.3 Obesity 
2.3.1 The size of the problem 
Obesity is not a new phenomenon. Throughout history a minority, often the 
most affluent in a society have been obese (Unger and Scherer 2010), and 
ancient physicians recognised links between obesity and diabetes (Tipton 2008; 
King and Rubin 2003). However, the last forty years has seen an increasing 
proportion of overweight, obese and morbidly obese adults in most countries in 
the world (Danaei et al 2011; Wang et al 2011; James 2008). Finucane and 
colleagues highlight that Body Mass Index (BMI), has increased by 0.4 - 0 5 
kg/m2 per decade between 1980 and 2008 in 199 countries (2011b). Although 
there are geographical and societal variations, this trend has spread from the 
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United States of America and is now a global phenomenon. Improved 
healthcare and an aging population in the west with globalization, urbanization, 
and economic development in developing countries leading to changes in 
lifestyle are cited as driving both the obesity and diabesity epidemics (Malik et al 
2012; James 2008; Kelly et al 2008). 
The Health Survey for England (NHS Information Centre 2012) showed that 
over half the adult population in England are now overweight or obese, 66% of 
men and 57% of women. Weight and BMI have remained normally distributed 
within the population but the whole distribution curve has shifted to the right 
such that 8 - 9% fewer adults were of normal BMI in 2009 compared to 1993 
and obesity has increased by the same percentage from 13% to 22% for men 
and from 16% to 24% for women. Consequently the perception of normality is 
changing thus an individual diagnosed with T2D may not consider dietary and 
lifestyle changes important because they see themselves to be of normal weight 
or not as ‘big’ as many of their peers without diabetes. Studies have shown 
familial, trans-generational trends (Pollard et al 2011) and that parents of obese 
children perceive their child to be normal weight (Regber et al 2013; Oude 
Luttikhuis et al 2010). 
Widespread acknowledgement that societal changes are fuelling the obesity 
epidemic have led organisations and authors to extol the need for concerted 
preventative action, global policies and coordination by governments, 
organisations, communities and individuals to positively influence behavioural 
change (Malik et al 2012; Hu 2011; Keeling 2011). Yet, the mechanisms by 
which these changes are driving the obesity epidemic is still debated 
(Ravichandran 2013; Taubes 2013). Education and advice to support individual 
behaviour change are proffered as a solution. Guttman and Salmon (2004) 
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highlight this may be counterproductive as it can reinforce self-blame and 
helplessness and thus elicit the opposite behaviour. Exhorting individuals to 
adopt a healthy lifestyle without taking into account the social and 
environmental factors that affects their behaviour can lead to a culture which 
blames and stigmatises the individual. Delormier and colleagues (2009, p.217) 
suggest that rational choice has little to do with peoples food choices as: ‘eating 
is embedded in the flow of day-to-day life’ and furthermore daily interactions 
within family and social groups at work and school shape peoples eating 
patterns. 
2.3.2 Food rationing to the obesogenic society in a generation  
Reflecting on changes in social and environmental influences over the life-
course of individuals may help explain these obesity statistics from a person 
centred approach (Devine 2005). Although T2D is being diagnosed at a 
progressively younger age, many of the people living with established T2D for 
five to ten years were diagnosed in their 50’s and 60’s they were therefore born 
in the late 1930’s to 1950’s. In the United Kingdom this generation experienced 
rapid changes from childhood food shortages and rationing during and 
immediately after World War II to increasing access to a variety of foods with 
mass advertising of convenience foods and fast food restaurants. This surfeit of 
energy dense foods became increasingly more available concurrently with 
dramatic changes occurring in society which resulted in reduced energy 
expenditure (Prentice and Jebb 1995). Working lives became more sedentary 
with increased mechanisation and a revolution in household appliances in the 
1950’s abolished much of the drudgery of housework whilst cold, draughty 
houses began to be replaced by energy efficient centrally heated homes 
(Corbishley 1993). Increased car ownership has reduced active transport to 
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work and school, whilst the development of supermarkets heralded the end of 
frequent trips on foot to local shops for fresh food (The Daily Mail 2013). Social 
eating outside the family home became more frequent with increasing affluence 
and social mobility for many from the late 1960’s (Warde 2000). Burnett (1989, 
p.318) reporting a classic survey of leisure activity in late 1980’s stated that: 
‘going out for a meal or entertaining friends to a meal at home were rated as the 
most popular occupations after watching television’. The link between these 
societal changes in eating habits and obesity may be explained by studies 
showing that marketing strategies of increasing portion and package size of 
restaurant meals and food products encourage higher consumption not only at 
that meal but for the subsequent 24 hours (Chandon and Wansink 2012; 
Vermeer et al 2010; Ello-Martin et al 2005). 
2.4 Social and cultural attitudes to food and meals 
Food choices are not governed by individual taste alone but are shaped in 
social and cultural contexts (Caplan et al 1998). Age, gender, ethnicity, religion, 
beliefs and socioeconomic background all influence attitudes to food and eating. 
Food and eating is primarily a social activity so life experiences and 
relationships add fresh dimensions which may encourage adaptation or 
reinforce existing preferences. Social interactions, settings and environments 
alter what, when and how much we eat (Sobal et al 2012; Wansink and Sobal 
2007).  
A qualitative study of food choice in older Irish adults (Delaney and McCarthy 
2011) found that social and historical circumstances as well as life experiences 
influence food choices in a myriad of ways and that enduring dietary habits can 
become firmly established in childhood. Early food experiences for this group of 
Irish adults were similar to other parts of the British Isles with food shortages 
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and meals prepared from basic home cooked local produce in their childhood. 
The participants recounted as there were no oranges or sweets they highly 
prized as they became available. In my clinical practice I have found that 
patients who remember food shortages and rationing often explain they have a 
‘sweet tooth’ and crave sweet things because they were in such short supply 
during their childhood. Some also recount that as children of the 1950’s they 
were told to finish everything on their plate as food should not be wasted. 
Traditionally women have been responsible for preparing and providing family 
meals. Studies by Charles and Kerr (1988) interviewing mothers of young 
children in the north of England in 1982/3 and in South Wales by Murcott 
1979/80 cited by (Kemmer 2000) found that women still considered it their role 
to provide the meals for the family. They spoke of ‘proper meals’ being a 
cooked meal consisting of meat, or fish and two vegetable servings, with the 
family sitting at the table, with a more elaborate version of roast meat on 
Sundays and celebrations such as Christmas. A salad or meal with bread was 
not a ‘proper meal’ more of a snack. Kemmer (2000) argues that the studies 
conducted in late 70’s and early 80’s were both historically and geographically 
located as well as very specific in the life-course of the women interviewed. She 
highlights the significant economic, social and political changes for women in 
Britain over the previous fifteen years, commenting that the ‘…rigid gendering of 
employment and domestic tasks is being broken down’ (Kemmer 2000, p.329). 
Contrasting these earlier studies with a study of young couples as they began to 
live together Kemmer (2000) notes these young couples in mid-1990’s share 
and collaborate over food related tasks but still consider it important to have a 
‘proper meal’ together when possible. Food diaries of younger couples 
demonstrated a shift from traditional meat with vegetables and a cooked 
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pudding to 23% of evening meals being pasta or rice based or light meals, 
whilst home cooked puddings were not featured (Marshall and Anderson 2002; 
Kemmer et al 1998). 
These studies two decades apart serve to highlight the importance of 
recognising broader influences on an individual’s food choices. Although 
conducted in the 21st century, responses in a study of older Irish adults by 
Delaney and McCarthy (2011) and another by Lawton (2008) of first generation 
Pakistani and Indian migrants living in the UK mirrored earlier work of Murcott 
(1982) and Charles & Kerr (1988), particularly the value of a ‘proper meal’. 
However, the migrant participants’ interpretation of a ‘proper meal’ was a 
cooked meal of their traditional foods. Participants of these later studies were a 
similar age cohort to those interviewed as young mothers 1979-83 and many 
individuals currently living with established T2D. For many of this generation of 
women providing family meals has been central to their role and identity. Brown 
(2012) found that women who were used to feeding a family found difficulty 
adapting their cooking to changed life events. 
Biscogni (2002) highlights that food is such an important element of our lives 
that people will often refer to themselves with reference to how or what they eat 
such as ‘I’m a vegetarian’ or ‘I’m a meat and two veg man’, ‘I’m a picky eater’ or 
‘I’m a big eater’. Others relate that they are known amongst family or friends 
and work colleagues as ‘someone who loves his food’ or ‘he enjoys a hearty 
meal’, these labels thus become part of their identity. Similarly some women, 
the traditional food providers mourn the loss of this identity when the family 
leave home. 
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2.5 Living with Diabetes 
2.5.1 Ambiguity and complexity 
In common with other chronic conditions, the daily management of diabetes 
relies on individuals living with the condition performing a range of complex self-
care behaviours, such as adhering to a healthy diet and lifestyle, monitoring 
blood glucose levels and taking medications appropriately (Forbes 2011). Thus 
management should be a collaboration between the person living with the 
condition and those providing care and support (Heinrich et al 2010; Funnell et 
al 1991). To prevent complications hyperglycaemia, insulin insensitivity, 
dyslipidaemia, hypertension and obesity all need to be addressed according to 
severity, yet from the perspective of an asymptomatic individual, they may need 
time to adjust to the diagnosis before engaging with education (Peel et al 2004). 
In a study of emotional reactions to a diagnosis of T2D Peel and colleagues 
(2004) found the participants would have liked more information, particularly on 
management of diabetes at diagnosis, but not too much about potential 
complications. Diabetes care for the majority of individuals with T2D in the UK is 
provided by a combination of consultation with a practice nurse and GP with a 
special interest in diabetes. Group education courses are delivered by a multi-
disciplinary team at diagnosis with practice based annual review and retinal 
screening. Access to specialist podiatry, dietetic and lifestyle advice and 
psychological support depend on priorities set within each locality and may vary 
according to funding initiatives and governmental targets over time. In the 
cross-national DAWN2 study of HCP’s perspective 60% reported the need for 
major improvements in self management education and in some countries less 
than two thirds of HCP’s had any formal diabetes training (Holt et al 2013). 
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2.5.2 Barriers and supports for self management  
Gomersall and colleagues (2011) highlight the increased prevalence of T2D 
relative to social deprivation in Europe and criticise the assumption that all 
individuals have the ability to instigate and maintain lifestyle recommendations. 
There is an increased incidence of T2D in individuals with depression whilst at 
least a third of people with diabetes have clinical depression (Roy and Lloyd 
2012; Renn et al 2011; Nouwen et al 2010). The added burden of depression in 
diabetes is known to contribute to poor self care, lack of adherence to 
medications and significant reduction in quality of life (Holt and Katon 2012; 
Lloyd et al 2012). Diabetes distress (DD), a measure of the emotional burden of 
diabetes, has been shown to adversely affect diabetes management even in the 
absence of clinically diagnosed depression (Fisher et al 2010). 
 Minet and colleagues (2011) acknowledge the importance of existing social 
and family support networks, especially at times of vulnerability, highlighting that 
when patients were dealing with problems and difficulties they found it difficult  
to mobilise resources. A systematic review of the literature (Rintala et al 2013) 
found both positive and negative aspects of family and spousal interactions. As 
dietary changes are part of diabetes treatment, a common theme was the 
gendered nature of food related tasks. Authors suggested that female partners 
of men with diabetes frequently take responsibility for adapting the food and 
cooking, often embracing healthy eating guidelines for the whole family, 
whereas women with diabetes attempt to balance the family food choices whilst 
denying themselves the ‘unhealthy choices’ (Rintala et al 2013; Broom and 
Lenagh-Maguire 2010; Peel et al 2005). In a study of spousal support of adults 
living with T2D, Beverly and colleagues (2008) reported that a female 
participant felt unsupported so she decided to prepare her own meals 
25 
separately and that although, many men welcomed support from their wives, 
some expressed resentment ‘I resent … her nagging.... a single piece of candy 
is like the black plague’ (Beverly et al 2008, p.712). Franks and colleagues 
(2012) found that spousal support to address dietary changes reduced DD for 
both, but if a spouse exerted pressure, they increased their own emotional 
burden without reducing DD for their spouse. The DAWN2 study of family 
members highlighted the distress and concern felt by family members of people 
living with diabetes (Kovacs Burns et al 2013). If couples shared meals the 
individual with diabetes found food choices easier, was more likely to have a 
good glycaemic control and suffered less DD than those who ate alone (Franks 
et al 2012). Similarly, family support aided initiation and maintenance of 
exercise (Rintala et al 2013).  
Lack of time, suitable facilities or pre-existing conditions which limit activity and 
for some groups, cultural norms were cited as typical barriers to physical activity 
(Lawton et al 2006). Whilst, Peel (2010) found that walking, especially walking a 
dog was most likely to be sustained long term. Malpass and colleagues (2009) 
highlight the value diet and physical activity information offered concurrently as 
increased physical activity may support other lifestyle changes.  
2.5.3 Compliance or informed choice and concordance? 
The progressive nature of T2D necessitates initiation or escalation of glucose 
lowering treatments in addition to initial diet and lifestyle changes to maintain 
glycaemic targets (Khunti and Davies 2010; Nathan et al 2009). Seventy five 
percent of UKPDS cohort required triple therapy within 9 years of diagnosis 
(Wright et al 2002; Turner et al 1999). Individuals may perceive this as a 
personal failure, particularly in the light of healthcare terminology such as ‘diet 
and lifestyle or sulphonylurea failure’ (Polonsky 2007a; Vermeire et al 2007). 
26 
For a person living with diabetes, implementation of new treatment regimes 
often triggers a re-evaluation of the seriousness of their diagnosis, reflecting 
that it is no longer ‘mild diabetes’ controlled with diet but a condition which now 
needs complex treatment. In a study exploring uncertainties inherent in T2D a 
participant encapsulated the choices people make as they become more aware 
of potential complications:  
I’m not certain that I can keep all of my limbs the longer we go 
along. You have to balance that with . . . if I cheat a little bit here 
then I have to lose a toe later. Is it worth it? (Middleton et al 2012, 
p.595).  
The side effects of diabetes treatments discussed in 2.2.3, gastrointestinal 
disturbances, potential weight gain and particularly fear of hypoglycaemia are 
cited as barriers to both timely initiation of treatment regimes and adherence to 
prescribed medication. There is significant risk of hypoglycaemia with insulin or 
sulphonylurea treatment, particularly with increasing duration of diabetes and 
age. An estimated 5000 individuals on sulphonylurea a year experience severe 
hypoglycaemia requiring emergency intervention (Amiel et al 2008; UK 
Hypoglycaemia Study Group 2007). Hypoglycaemia adversely affects quality of 
life and all activities of daily living including work, driving, leisure time and 
restricts dietary freedom. Hypoglycaemia and fear of hypoglycaemia have been 
shown to undermine confidence, compromise self-care and limit efforts to 
achieve glucose and weight loss targets (Barendse 2012; Peyrot et al 2012; 
Khunti and Davies 2010). Donnelly and colleagues (2007) noted that non 
collection of insulin prescription was related to poorer glycaemic control in T2D 
which may indicate a deliberate choice to reduce or omit their insulin doses 
following hypoglycaemic episodes. Kripalani (2007) highlights that in chronic 
conditions poor medication adherence is linked to worse clinical outcomes and 
increased healthcare costs a pattern also observed in T2D (Cramer 2004). 
27 
Although there are many references to compliance or adherence to treatment 
plans in the diabetes literature, Anderson and Funnell (2000) suggest this is 
inappropriate for a self-managed condition. The person living with diabetes will 
make informed choices according to their own priorities and are therefore 
compliant in their own terms, HCP’s need to provide information and support to 
ensure these choices are fully informed. As Snowden and Marland (2013) 
highlight the King’s Fund report advocates shared decision making ‘no decision 
about me without me’(Coulter and Collins 2011). Discrete choice questionnaires 
used to assess the weight individuals place on differing symptoms against a 
balance of improved glycaemic control for T2D, demonstrated a preference for 
treatments with lower risk of hypoglycaemia, weight gain or gastrointestinal side 
effects (Gelhorn et al 2013; Hauber et al 2009).  
2.6 Summary 
This chapter has highlighted complex physiological and societal influences 
which impact on human health with a particular focus on an individual living with 
T2D. With increasing options for diabetes management it is now possible to 
work collaboratively with the wishes and needs of the person with diabetes to 
individualise their personal targets and treatment plan (Kruger 2012; Peters 
2012). In order to achieve this, HCP’s need a better understanding of the mode 
of action of different medications and likely impact of any side-effects on the 
lifestyle of the individuals living with diabetes. Studies exploring the lived 
experience of medication usage such as the EAT study will inform practice.  
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Chapter 3 – Methods and Methodology 
3.1 Introduction 
I present Chapter 3 as a ‘natural history’ of the research, consistent with 
the approach of Silverman (2010). The impetus for the study began as 
described in Chapter 1.3 and Chapter 2.1 from observations as a clinical 
research nurse initiating GLP-1 analogue therapy as part of a clinical trial 
(Davies et al 2009). Although GLP-1 analogue therapy has been shown 
to decrease energy intake in healthy volunteers (Verdich et al 2001; Flint 
et al 1998), no studies included investigation of particular individual 
dietary response in T2D. I reflected that participants in my practice, who 
improved their glycaemic control and reduced weight, reported adapting 
their eating habits in response to study medication. I wondered if a factor 
associated with good clinical outcomes could be individual responses to 
newly discovered satiety during meals and whether their experience 
could inform future practice and formulated my initial research question; 
 To explore the most appropriate dietary and lifestyle advice to 
enhance the efficacy and tolerability of incretin analogue treatment in 
T2D 
with a secondary question of; 
 Can food choices explain why some patients with T2D fail to respond 
to incretin analogues therapy? 
To address the question I felt a qualitative methodology to be the most 
appropriate as it is frequently employed to explore the personal or 
individual response to phenomena, to gain a deeper understanding or in 
exploratory scenarios (Silverman 2011; Creswell 2009; Denzin and 
Lincoln 2000). I designed a study to address the question, the study aims 
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being to use the ‘lived experience’ of a group of ‘expert users’ of GLP-1 
analogue therapy to: 
 Explore how changes in appetite induced by GLP-1 analogue therapy 
in T2D influenced dietary choices.  
 Identify whether people treated with GLP-1 analogue therapy develop 
strategies to moderate side effects. 
A more detailed description and rationale for my choices of qualitative 
research design, data collection and sampling strategy follows in section 
3.3, with subsequent sections detailing funding and ethics, recruitment 
and participants, focus group dynamics and approach to data analysis.  
Conscious that the research was shaped by my own past experiences and 
personhood (Letherby et al 2013; Swift and Tischler 2010; Letherby 2004), I 
include a short biography of my career path.  
3.2 My Background 
Twenty seven years ago I took my first steps in diabetes research when 
appointed as clinical research nurse at a district general hospital, responsible 
for establishing and running one of 23 recruiting centres for an academic RCT 
in new onset T2D, the UKPDS (1998d). I was fascinated and knew I had found 
my ideal job. My workload involved balancing study recruitment and provision of 
on-going care with support and education for individuals with a new diagnosis of 
T2D. The study grew organically; after three and a half years recruitment, 195 
patients were receiving their regular clinical care whilst contributing 
enthusiastically to the research cohort of 5,102 individuals. The research clinics 
became a lively hubbub of the multi-disciplinary team meeting research 
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participants as old friends whilst addressing clinical needs, conducting 
assessments and collecting research samples and data. 
Neither I nor the people who kindly volunteered realised we would be involved 
in a 20 year journey contributing to a landmark study in T2D providing the 
evidence base for current treatment aims (Holman et al 2008; Stratton et al 
2000; UKPDS Study Group 1998c, 1998d, 1998a, 1998b). Collaboration 
continued with Oxford Clinical Trials Unit contributing to other diabetes studies 
whilst developing our own studies exploring different dietetic approaches and an 
RCT of group education and lifestyle support (Daly et al 2006; Paisey et al 
2002). When government funding in 2006 established a research network in 
diabetes (DRN) at national and local level, our diabetes research team became 
one centre of initially four in the South West Peninsula Local Diabetes Research 
Network (SWPDRN). 
3.3 The Research Design 
3.3.1 Methodological choices 
The multi-national programme of research leading to the licensing of exenatide 
for human and clinical use followed the recognised pathway within medicine 
and healthcare from lab bench to patient (Davies et al 2009; Drucker and Nauck 
2006; Elrick et al 1964) to establish efficacy and safety of a new drug or 
intervention. Although quantitative questions related to side effect profile and 
‘quality of life questionnaires’ were employed, the impact for an individual 
attempting to integrate this new form of treatment into their lifestyle, can be lost 
when data is presented as statistical means and standard deviations. As Hardy 
and colleagues citing Greenhalgh (2006) highlight there is a dilemma for HCP’s: 
 ... upholding the individual narrative in a world where valid and 
generalisable truths come from population driven evidence (Hardy 
et al 2009, p.9).  
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They argue that:  
... empirical population based observation about illness cannot be 
applied directly to individual patients, whose behaviour is 
contextually driven and idiosyncratic (Hardy et al 2009, p.9).  
In social sciences and nursing research this dilemma is addressed by changing 
the focus from the broad based, experimental analysis of large statistically 
measureable variables of the quantitative research paradigm to a qualitative 
approach which seeks to explore the personal or individual response to 
phenomena in natural settings (Creswell 2009; Silverman 2004; Denzin and 
Lincoln 2000). This interpretive, descriptive approach of qualitative research has 
evolved from different social science traditions, initially philosophy, 
anthropology, history, sociology and psychology with differing epistemologies 
and methodologies (Silverman 2011; Flick et al 2004; Brewer 1989). Qualitative 
research has been espoused and adapted by other professionals including 
those in healthcare to suit their needs (Holloway and Wheeler 2010; Morse 
2010; Bowling 2009). Sparkes (2005) suggests that when a practitioner attends 
to the individual story told by those who experience healthcare, it can 
significantly improve daily practices, identifying themes which affect the 
person’s quality of life, paving the way for meaningful person centred care. 
Whilst Galvin and Todres (2011, p.523).agree, they propose combining 
phenomenological methodology with empathic nursing knowledge to develop a 
way of knowing ‘that is inclusive of the head, hand and heart’ to provide holistic 
care  
3.3.2 Data collection choices 
Conscious that research design and methodology should be appropriate for the 
research question (Silverman 2010; Holliday 2007; Letherby 2004) my 
experience and background reading suggested that qualitative methodology 
would be the most appropriate design to allow a thorough exploration of the 
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issues surrounding taking incretin analogue therapy and thus provide insight 
into the impact of this type of medication.  
In-depth interviews are frequently employed within healthcare research as they 
have the potential to gather rich data, exploring experiences, beliefs or 
phenomenon from the participants’ perspective, particularly where little is known 
of the subject (Silverman 2011; Holloway 2005). Individual interviews are 
flexible and offer the opportunity for the researcher to probe and clarify 
participant responses, however gathering data can be costly both in time and 
resources (Holloway and Wheeler 2010). Tod (2006) cites Field and Morse 
(1985) when she cautions that role conflict, particularly for nurses or other 
clinicians conducting research with less structured interviews can be difficult to 
avoid. I suspected that as a nurse proposing my own study there would be 
difficulties securing funding and sufficient time to conduct in-depth interviews. I 
was also concerned that as some of the potential participants were known to 
me as patients and participants in previous clinical studies there would be 
potential for role conflict and power imbalance in a setting not too dissimilar to a 
clinical consultation (Karnieli-Miller et al 2009). 
Following exploratory discussions with some of the participants from the HEELA 
study and colleagues, I recognised that it was difficult for either an individual 
using exenatide or their HCP to articulate how appetite was affected and what, 
if any changes were made as a consequence. Despite this I believed there was 
potential to explore the ‘lived experience’ of experienced users of this relatively 
new medication and use their pooled knowledge to support future care. 
Previous experience as a group facilitator both in research and education 
settings (Daly et al 2006; Paisey et al 2002) taught me the value of group 
discussions to facilitate insight and understanding. Group dynamics in small 
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group discussions of ‘expert users’ in a focus group, may prompt and generate 
a previously unrecognised shared knowledge (Green 2004; Morgan et al 1997). 
Focus groups are particularly suited to exploratory research in healthcare, 
especially experiences of specific topics or treatments (Greaney et al 2012; 
Gerrish and Lacey 2006; Kitzinger 2005). Goodman and Evans (2006, p.362) 
suggest that this ‘exploratory and illuminatory function’ of focus groups can 
extend and enrich understanding.  
There are enthusiastic proponents of individual in-depth interviews and of focus 
groups to gather evidence (Kitzinger 2005; Greenbaum 2000). Goodman and 
Evans (2006) suggest that the synergy of group discussion may enable a more 
enthusiastic consideration of a topic by participants than individual interviews. 
This view however is contested, as is whether sensitive issues may also be 
more readily discussed within the safety of a group setting (Kitzinger 2005; 
Farquhar 1999; Michell 1999). Weighing the advantages and disadvantages of 
interviews versus focus groups for my research question, potential participants, 
the resources available and my skills, I considered focus groups were the most 
effective method of gathering rich data within the time and funding available. I 
felt that as a researcher asking participants to share their experiences as 
‘expert users’ within a focus group would allow me to discard my ‘specialist 
nurse hat’ for that of a group facilitator. This strategy would therefore respect 
the participant experience and neutralise a potential power imbalance inherent 
in many clinical or research settings (Karnieli-Miller et al 2009; Richards and 
Emslie 2000).  
3.3.3 Sampling strategy and final study design  
A purposeful sampling strategy was employed to recruit participants with 
successful experience of incretin analogue therapy by identifying individuals 
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known from the previous research study and by referral from the clinical team. 
Two focus groups of four to seven people were planned to be small enough to 
allow free and open discussion but large enough to help generate ideas and for 
themes to emerge (Greenbaum 2000; Morgan et al 1997; Krueger 1998a). 
The original study design was to audiotape group discussions augmented by an 
independent note taker advocated by research texts as the least obtrusive 
method of recording (Greenbaum 2000; Krueger 1998b). However, as I was 
able to utilise an audiovisual recording suite recently installed for clinical training 
scenarios in the education and research department, I amended my plans. 
Although initially anxious that audiovisual recording would be too intrusive my 
fears were allayed on reviewing the equipment. It was flexible and reliable with 
three multi-directional cameras controlled from an observation room therefore 
very discrete, additional microphones could be placed around the room or worn 
by group members, offering excellent sound recording (Goodman and Evans 
2006). Digital recording was direct to secure computer with immediate backup 
to my password protected secure confidentiality compliant NHS account. Using 
this equipment would be less intrusive, provide better quality data, including the 
ability to record non-verbal information and complied with confidentiality and 
data protection regulations (Johnson and Long 2006). 
3.4 Funding, sponsorship, ethical and trust approvals 
Having been awarded a grant for my own research proposal and with a place 
on a research masters course I applied for the university to sponsor the 
research and to the National Research Ethics Service (NRES) South West 
committee for approval. Approval was granted subject to clarification of the 
proposed audiovisual recording analysis ref: SW/11/0107. Hospital Trust and 
R&D approval quickly followed: (R&D) agreement ref: 11/06/016. This enabled 
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me to negotiate using the research grant funds to backfill one session a week to 
facilitate dedicated time for the EAT study and to approach and consent hospital 
patients as participants (Johnson and Long 2006).  
3.5 Recruitment and Consent  
Potential participants were identified from previous research and by referral 
from clinicians. The ‘experienced’ users from an earlier study had given written 
consent to be approached for future studies, enabling me to make a direct 
approach. Other potential participants had either consented to be approached 
for research or were invited by the clinician providing their routine care, thus 
maintaining confidentiality of personal and clinical data. The initial approach 
was by letter with my contact number and a reply slip (appendix I) with stamped 
addressed envelope. A positive response was followed up by a telephone call to 
establish eligibility and willingness to consider participation. Those interested 
were offered individual appointments to discuss and sign study consent with 
prior mailing of participant information and example consent form (appendix II, 
III) to arrive at least 48 hours before the visit. I took the opportunity to discuss 
which days and time of day to they were able to attend focus groups so I could 
schedule groups to suit the majority of participants.  
For some studies the need to rely on gatekeepers can be problematic, 
especially if these gatekeepers do not understand or agree with the research, 
feel it is not their role or that they need to protect their patients. The recruitment 
process can thus be biased or delayed (Nugus et al 2012; Holloway and 
Wheeler 2010). I did not encounter a problem and was able to begin consent 
visits in July continuing until November 2011. 
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3.5.1 The Participants 
I use the term ‘participants’ for the people who consented to take part in this 
exploration of their experience of incretin analogue therapy and ‘patient’ if 
discussing a general clinical scenario or encounter with HCP’s. Participant is 
the preferred term within healthcare research for individuals who volunteer for 
research, as it expresses collaboration in recognition that they have agreed 
voluntarily by a process of informed consent to participate (Holloway and 
Wheeler 2010). This use of participant is also reflected in the terminology used 
when applying for research ethical approval in healthcare.  
The EAT study took place in a district general hospital in the south west of the 
UK with a population of nearly 300,000, a high percentage of retired residents, 
with rural communities and pockets of social and economic deprivation and very 
few non-white British residents. Tourism, farming, fishing and light industry are 
the main sources of employment. Socio-economic details were not collected as 
part of the research process although some participants volunteered information 
during the discussion. Although not selected to be representative, as the 
sampling was purposive, age, gender and ethnicity reflect the composition of 
the local population with T2D requiring triple therapy. A short anonymised 
biography of each participant by group composition appendix VI has been 
removed to further protect participant anonymity, whilst a summary table can be 
found in appendix VII 
All names have been changed to respect anonymity of the participants. Bert, 
Adam Bob and Gerald all started on exenatide as part of the HEELA study 
(Davies et al 2009) prior to UK licensing of the first of the incretin analogue 
therapies. It was my experience as a research nurse recruiting to this study that 
was the catalyst to explore the effects of this new treatment from a patient 
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perspective, with particular emphasis on their adaptation to changes in satiety. 
Betty, Maud and Johnny all started on exenatide soon after it became available 
on prescription in the UK. These were the seven experienced participants with 
30 to 52 months incretin analogue use at the time of consent. Participants, 
Ruth, Cath, Laura, Lionel and Mavis were referred by their consultant and Mark 
referred by his family doctor, had 12 to 24 months experience. Luke and Linda 
who had started incretin analogue therapy within three to seven months of the 
focus group were referred by their diabetes specialist nurse by another research 
nurse respectively. 
As discussed the research idea grew from my work and awareness of an unmet 
need, these individuals were the only potential pool of ‘expert patients’ who 
were using incretin analogue therapy at the time. I was acutely aware of the 
dilemmas this raised, particularly insider/outsider privilege, the potential for bias 
and power imbalance (Holloway 2005; Silverman 2011). I attempt to highlight 
these conflicts throughout. 
3.5.2 Organising venue and establishing focus groups 
The decision to use the audiovisual recording equipment defined the choice of 
venue. This had the advantage of being in hospital grounds with level access, 
disabled toilet facilities, close to public transport and parking but away from 
clinical areas. I was able to organise refreshments, ensure we were not 
interrupted and be confident that the recording equipment was high quality, 
serviced and well maintained. The clinical nature of the room was a 
disadvantage but, I was able to screen the clinical equipment to the edge of the 
room and found that apologising for and explaining the purpose of the room for 
clinical skills training, proved a useful icebreaker as participants gathered. 
Although not ideal, the pragmatic choice was to ensure good quality, secure 
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recording, ease of access, freedom from interruptions and ability to offer a 
choice of times and dates for groups (Greenbaum 2000; Krueger 1998a). 
Co-ordinating availability of the audiovisual suite, a colleague with experience to 
use the recording equipment and another to act as independent note taker, with 
times when a group of consented participants were able to attend was a 
logistical challenge. I anticipated the problem from experience and reading of 
research texts (Greenbaum 2000; Barbour and Kitzinger 1999; Krueger 1998a) 
so had a choice of tentative dates and times arranged when recruiting and 
consenting participants. The resulting composition of the first two groups 
included by chance a similar gender, age and duration of diabetes profile. 
However, rather than one group with more experience and a second with 
shorter use of incretin analogue therapy, there were experienced users in both 
groups. Five participants were able to attend each of these groups but one 
experienced participant although very keen to contribute was unable to attend, 
he was included in a third group. 
Since the planning phase of the project, prescribing practice had changed with 
initiation of exenatide allowed in primary care and a second incretin analogue 
based treatment (liraglutide) introduced. I informed the hospital trust R&D 
manager of my intention to recruit a third group, to purposively sample 
participants with more recent experience of starting incretin analogue therapy, 
especially within primary care. This strategy allowed me to enrich the data and 
assess whether their insight would differ significantly from the data already 
collected (Holloway and Wheeler 2010; Kitzinger 2005; Barbour and Kitzinger 
1999). 
  
39 
3.6 Conducting focus groups and group dynamics 
Each group of five participants was held in the venue described with the same 
colleague taking notes, facilitated by myself and audiovisually recorded. All 
participants were aware from initial contact and supporting information of the 
aims of the research. I had discussed during the consent process that they were 
invited as part of a focus group to meet and discuss with others, their 
experience and the impact of using incretin analogue therapy, they had all 
therefore had time to reflect and came prepared. As each group arrived I 
introduced them to my colleagues recording the discussions, highlighted the 
position of cameras and microphones and offered refreshments. As facilitator of 
all the groups, I began with a similar introductory sentence thanking everyone 
for their time and willingness to share their experiences, reminding them that 
they were the experts and that my role was to gather their combined ‘gems of 
wisdom’ with a hope to use the information to improve future practice. I 
described the combined years of living with diabetes and months of incretin 
analogue therapy use within that group to emphasise their expertise and shared 
knowledge. I explained that in wider use a percentage of individuals found side 
effects of this new medication difficult and invited the group to discuss their own 
experiences and any strategies they had developed to overcome problems. I 
facilitated and encouraged open discussion allowing ideas and themes to 
emerge, ensuring all participants had the opportunity to contribute (Greenbaum 
2000; Krueger 1998a). A semi-structured interview guide (appendix VI) ensured 
all topics were addressed. 
Each individual has a different story, their interactions with others in a group or 
with a researcher will inform how they choose to tell that story and external 
influences may impact differently in each situation. Despite my best efforts each 
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of the groups had disruptions or delays described below that will have impacted 
on the participants and my facilitation of discussions.  
The start of the first group (g1) was delayed over 30 minutes waiting for my 
colleague note taker to arrive. This proved a fruitful time to allow participants to 
relax and introduce themselves over refreshments, these interactions were not 
recorded nor any notes taken. When she arrived we moved quickly into starting 
the focus group discussion and recordings, initially the participants became 
reserved and felt the need to take turns to contribute, the spontaneity of the 
earlier exchanges having been lost. However with prompting a lively discussion 
developed of how to manage appetite changes in a social setting and how 
attitudes to food had been shaped by childhood and other experiences 
(Kitzinger 1994). The resulting recording and data collection was the shortest 
for this group lasting 45 minutes. 
For the second group (g2), many of the group arrived early and were greeted by 
my colleague who introduced herself over refreshments. I came directly from 
clinic without time to change out my nurses’ uniform. The wife of one of the 
participants asked if she could join in, as she had recently been diagnosed with 
diabetes, the other participants agreed and welcomed her and another of the 
participants in this group was an HCP. On reflection these three factors 
influenced the group dynamics making it more difficult keep the focus on the 
participant experience as expert users. After the initial introduction and invitation 
to share experiences, a lively exchange about benefits of treatment and 
improvements in diabetes control or weight loss ensued. However, after 40 
minutes, the wife who had asked to watch and listen began answering for her 
husband and referring to herself as the ‘food police’. Drawing in a participant 
who had been quiet, I realised too late he was irritated by her comments and he 
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became quite challenging. This exchange unsettled the whole group, it took a 
few minutes to bring the group back to sharing experiences and the research 
question (Goodman and Evans 2006; Joseph et al 2000). More clinical issues 
were discussed within this group, possibly because I was in uniform and it 
included another HCP who was inclined to intervene with clinical responses. 
However, I was able to use the group dynamics to refocus the discussions 
which, perhaps to compensate for the previous dominance were lively and 
varied (Joseph et al 2000; Kitzinger 1995). The group lasted one hour twenty 
five minutes 
The third group (g3) was also delayed waiting for late arrival of a participant. 
Recording started as the group assembled so introductions and explanations 
were captured. After allowing ten minutes I began the main group discussions, 
we were interrupted twice first by a fire alarm test and again when the last 
participant arrived. Despite these interruptions this group quickly settled into 
sharing their experiences. As two of the participants were relatively new to 
incretin analogue therapy they were still coming to terms with its action and the 
impact it had on their eating pattern was still fresh. The value of the group 
exchanges in recognising the impact and support from others in the group was 
evident (Joseph et al 2000). Interesting exchanges related to side effects of 
other diabetes treatments as well as benefits of incretin analogue therapy 
provided lively discussion only halted by arrival of tea and refreshments. 
Discussions continued over these refreshments, the meeting lasted one hour 
forty five minutes. 
3.7 Approach to data analysis 
Following each focus group, the note taker and I exchanged initial thoughts on 
group interactions, important themes and if anything could be improved for 
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subsequent groups. I ensured the discussions had been successfully recorded 
and saved securely, watched the recording to check all aspects had been 
clearly captured and to reflect on my facilitation of the meeting, making notes 
whilst all was fresh in my mind. Any new ideas were noted to integrate into the 
schedule for future groups (Kitzinger 2005; Krueger 1998c). 
Duggleby (2005), Webb and Kevern (2001) highlight that despite group 
interactions being the generator of data in focus groups, these interactions are 
rarely analysed or reported. However, Morgan (2010) suggests that although: 
‘... saying that the interaction in focus groups produces the data is not the same 
as saying that the interaction itself is the data’ (Morgan 2010, p.718). 
I used two different phases to analyse the data. Firstly to ensure I captured the 
group, its dynamics and influences and early themes to feed back into ongoing 
data collection and later in more depth the individual story. Initially I watched 
and listened to the recordings several times in order to immerse myself in the 
data, first for an overview, then watching the ebb and flow of conversation and 
interactions and a third time listening more intently for emerging themes 
(Richards 2009; Pope and Mays 2006). To capture the focus group interaction I 
imported the audiovisual recordings into NVivo 9 research software. Using the 
computer software package facilitated coding of sections of the recording 
relating to specific topics of discussion enabling frequent replay to observe 
concordance or disagreement within the group setting (Kitzinger 1994). As three 
cameras had captured the group from different angles I could assess non verbal 
communication and reactions of all participants and make appropriate notes 
and memos to include in analysis (Lehoux et al 2006; Duggleby 2005; Hyden 
and Bulow 2003; Webb and Kevern 2001). Whilst I was absorbing the broad 
overview of the group interaction, I organised for the first two recordings to be 
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transcribed verbatim by a professional NHS secretary ensuring confidentiality 
and independent verification of the text. I checked the transcripts for accuracy 
against the original recordings, substituting pseudonyms and anonymising all 
identifiable aspects of participant contributions then imported into NVivo. I was 
able to share pseudonymised transcripts with my supervisors to discuss coding 
and emergent themes whilst maintaining confidentiality.  
To change the focus from the broad overview of the group to allow the voice of 
each individual to surface (Morgan 2010; Duggleby 2005; Kitzinger 2005), I 
read the transcripts and hand coded them (Richards 2009; Krueger 1998c). 
These codes were added to the project in NVivo as nodes, and the 
pseudonymised participant log as cases. As each group was recorded and 
transcribed I immersed myself in the data again, watching and listening to the 
recordings and re-reading transcripts to discover themes revealing the impact of 
incretin analogue therapy and how these participants integrated this into their 
lives. I was now so immersed in the data that I found reading and coding by 
hand allowed me to follow threads and amalgamate codes into categories and 
eventually themes, moving up from the data (Richards 2009; Miles 1994). 
These insights were input into NVivo which allowed me to cross check 
consistency of coding across time and transcripts, display coding densities and 
integrate the different strands of analysis. These themes are presented with 
extracts of the participant contributions in the next chapter. 
3.8 Summary 
In this chapter I have explained the path that led me to the research question, 
how and where I conducted the study and my method of data analysis. I 
provided a short introduction to the participants, their voices will explain in 
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chapter 4 their experience of GLP-1 analogue therapy and changes in appetite 
and diet.  
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Chapter 4 ‘I used to eat and eat - now I just eat less’ 
4.1 Introduction 
In this chapter I present my analysis of the data set within a framework of 
existing evidence and understanding. Three broad themes emerged from 
analysis; the experience of ‘A Changed Relationship to Food and Eating’ set in 
context with links and interactions to both ‘The Medical Experience’ and ‘Social, 
Cultural and Emotional Influences’ (figure 1). Effective self-management of 
diabetes requires an integration of all aspects of the ‘routines of daily living’ 
(Anderson and Funnell 2010) so references to food and eating and the medical 
experience are entwined in every aspect of the analysis and are expressed 
within the context of each individual’s social, cultural and emotional influences 
of their life-course (Bisogni et al 2005; Devine 2005). Extracts focussing 
primarily on each theme will be discussed below. 
Figure 1 Three themes 
  
A Changed 
Relationship to Food 
& Eating  
Social, Cultural 
& Emotional 
Influences 
The  Medical 
Experience 
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4.2 A changed relationship to food and eating 
Food is necessary for survival yet excess causes increased health risks (Smith 
2002). The global rise in diabetes has shadowed a rising trend in obesity fuelled 
by an increasingly sedentary lifestyle and changes to traditional diets (Malik et 
al 2012; Hu 2011). Similar rapid changes to a less active lifestyle and greater 
access to energy dense foods has been mirrored in the UK during the latter half 
of the twentieth century, the life of the study participants. Delivery of diabetes 
services, including education and support has evolved as evidence and 
resources allowed (Davies et al 2008; Deakin et al 2006; Trento et al 2004; 
Funnell et al 1991). Consequently experience of dietary advice and support for 
self-management, which underpins all other treatments in diabetes, has varied 
according to time and location of diabetes diagnosis for the study participants. 
Peel (2005) highlights research by Sullivan and Joseph (1998) that people living 
with diabetes find the suggested dietary changes the most difficult aspect of 
their self-management to initiate and maintain. 
4.2.1 Satiety  
Hunger and appetite 
Some participants experienced dramatic changes in appetite that helped many 
achieve lifestyle changes that they had previously struggled to implement. 
Johnny described his insatiable hunger despite eating large meals before 
starting GLP-1 treatment: 
The injections lowered my appetite so I cut down on my portion 
size, ... because I could pile my plate high with a 12 - 14oz steak 
with a big jacket potato and loads of veg and a big pudding and 
still feel I wanted more. ... Now I have trouble getting through a 
4oz steak with a small helping of veg and a small jacket potato ... 
and the sweet comes maybe later in the evening. 
Johnny’s comments prompt Mark to recount with passion how hungry he used 
to be. He raises his voice with anger at the end of the phrase:  
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That’s the area that I’ve noticed a change in... before I came onto 
exenatide, I was on quite high insulin and I was always hungry 
and I could finish a meal and still feel hungry.  
Mark expands on the consequences of constant hunger and his drive to eat: 
... of course because you feel hungry, if you’re busy you don’t 
think about it you just grab something and you’re eating all the 
time. … but that constantly feeling hungry has gone ... at times 
we’d gone out and have a meal ... before we’d get back home I’d 
be thinking I’ve got to have something to eat, ... it was a real 
hunger. 
He considers the change was an effect of GLP-1 treatment not his own volition:  
... that has totally gone I just don’t feel that anymore and I can 
only, I put that down to exenatide, that’s not me saying I’ll cut this 
out I’ll cut that. 
Sophisticated physiological mechanisms including satiety and satiation help 
maintain energy balance and a healthy body weight (De Silva and Bloom 2012; 
Benelam 2009). However, in T2D the complex balance of metabolism is 
disturbed (Nolan et al 2011; Stumvoll et al 2005) including reduced levels of 
incretin hormone GLP-1. This may explain these descriptions of hunger and 
lack of satiety and subsequent reversal, as research has shown that the 
physiological actions of GLP-1 including reduction in hunger and increase in 
satiety are diminished in T2D (Nauck 2009; Holst 2007; Druce et al 2004). 
Johnny feels that GPL-1 treatment has helped him discover a previous 
unknown sensation of satiety: 
...that was the best thing that happened to me, because I can 
never remember not being hungry. You know always eat a meal 
and I’d feel hungry... If I don’t eat I don’t feel hungry, the minute I 
put food in my stomach I feel hungry. 
Others in the group agreed with Johnny that they had lost the sensation of 
constant hunger. Linda arrived after this exchange but she recounted the same 
experience. She expressed concern that her 25 year old son experiences a 
similar lack of satiety: 
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... I’m never ever full up. I could eat all day long and I never ever 
felt full up. My son is 25 and his wife will say ‘... what’s the matter 
with you?’ and he’ll say ‘well I’m not full, I don’t feel full’ and that’s 
how I was I could have ate meal upon meal and it was ... surely 
you’re not hungry? Yeah and it was actually I’m starving! 
Linda reported that after two weeks of GLP-1 treatment the hunger constant 
disappeared: 
Two weeks then all of a sudden overnight and I went from I would 
have raided anything I could have eaten to actually no I don’t feel 
hungry.  
Johnny reiterated his experience to support Linda, whilst Mark raised his voice 
to emphasise his point: 
Johnny: You actually get the hunger pains ....I’m abnormal there’s 
something wrong with my wiring in my brain 
Mark: It really is HUNGER, it’s not just ‘I fancy something’ I’ve got 
to eat.  
The orexigenic effect and weight gain associated with insulin and sulphonylurea 
treatment of T2D is well documented (Nayak et al 2010; UKPDS Study Group 
1999, 1998d), whilst hyperglycaemia as such may also increase appetite 
(Cugini et al 1996). This lively discussion around changes from a previous 
insatiable hunger to satiety in g3 was mirrored by some but not all in the other 
groups, although all spoke of feeling full. Betty in g1 also experienced a 
dramatic change in her appetite: 
I like food I really like food and then was like 13 stone ....so Dr P 
give me my new injection ... I lost a stone first couple of injection. 
And I used to eat and eat and now I just eat less. 
Adam disagreed, he did not recognise having experienced hunger but did 
acknowledge that he was renowned for eating large portions, something he is 
no longer able to do: 
I can’t remember ever being hungry... because I used to eat an 
enormous amount. When we go to see people who have been 
used to cooking for me in the past ‘oh Adam’s coming let’s make 
sure there’s plenty in’. 
He added that he still enjoys his food: 
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But I almost obtain an amount of almost sensual pleasure from 
eating.  I like eating and I like food.  I don’t think I’ve ever eaten 
because I’m hungry I eat because I like food and it’s something I 
enjoy. 
However, for some this new found satiety is not without consequences as now 
explained. 
Lack of interest in food  
Linda is still adapting to these changes after only three months of GLP-1 
treatment:  
I never actually fancy anything, it’s like well what shall we have for 
tea? Actually It wouldn’t bother me if I didn’t have anything at all 
...so that yea whereas before I’d be cor what am I going to have 
but now it’s like I don’t fancy anything at all it’s a case of you know 
you have to eat so you eat it. 
After nearly two years of GLP-1 treatment Cath and Ruth still have little interest 
in food and find it difficult to think what to eat: 
Cath: I used to have a um good appetite, I wouldn’t say I’d always 
eaten a lot, ... I’ve only had breakfast, dinner, tea or lunchtime and 
dinner in the evening. ... My eating habits have changed quite a lot 
because I find now a lot of things that I used to like I now can’t eat 
which is a bit odd I feel.  
Ruth: I find I don’t really get hungry as such until the evening 
really. Sometimes I can have just like maybe a biscuit for my 
breakfast and take my pills and then I won’t eat until the evening 
because I’m just not hungry. 
Adam also acknowledges a lack of interest in food and admits that he eats 
because it’s meal time rather than because he is hungry but reflects that this 
has always been the case:  
But still there is that question that I eat cos it’s breakfast time or 
lunchtime or supper time. .. I might not fancy anything to eat in the 
evening but I’ve got to have something because I’ve got to have 
my tablets and I’ve got to have them with food.  
For further examples and discussion of the emotional and social consequences 
of these changes see section 4.4. 
Recognition of Satiety  
Although studies of GLP-1 treatments describe the physiological mechanisms of 
increased satiety, how this is recognized by the individual is not discussed 
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(Barnett 2009; Nauck 2009). However, authors from other disciplines have 
explored satiety from physiological, societal, behavioural and external factors 
(Benelam 2009; Booth 2008; Kral 2006; Ello-Martin et al 2005; Diliberti et al 
2004).  
One of the aims of the EAT study was to explore whether the experience of 
these participants could inform future support and advice. Betty (some clinical 
details removed to protect participant anonymity) vividly described how her 
appetite changed once she started on exenatide:  
I used to eat and eat and now I just eat less and if I feel like 
hungry, more... I couldn’t even finish me plate I just left it. My 
tummy does actually say ‘O yes, I’ve completely had enough’ and 
I can’t eat any more.  
This change in behaviour after a lifelong struggle with attempted dietary 
restrictions has helped Betty achieve a 17.9 kg weight loss, and significantly 
improved her glycaemic control despite stopping insulin. She also reports it has 
transformed her life, she is more alert and active as a result, she is proud of her 
success: 
So now and now I’m nearly down to ten and a half stone…. I used 
to be in extra large clothes could never get in jeans and now I can 
get in jeans now and I’m sixteen in clothes and I’ve lost quite a lot 
in weight. 
Luke had been prescribed GLP-1 treatment seven months earlier, he initially 
had side effects so his dose was reduced for a few weeks. Dose titration at 
initiation of exenatide or liraglutide is recommended to reduce gastrointestinal 
side effects (Blonde and Montanya 2012). He described recognising that he 
needed to adapt his portion size when the dose was increased again: 
... but I couldn’t eat as much, you get a lot of pain in your stomach, 
and feeling sick, so I stopped eating that much ... I never got it so I 
had the pain in my stomach or the sickness. 
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However, others had difficulty recognising the sensation of satiety. Gerald 
described an initial improvement in diabetes control without weight loss, until a 
hospital admission after seven months on exenatide. His comments below 
highlight that hospital portion sizes helped him readjust: 
Oh that was the best three weeks I’ve ever had, lost a stone and a 
half. There’s nothing wrong the food here, no I mean it, … but it’s 
great food. 
Roz: Because of the smaller portion? I remember you saying to 
me that you got home and said to your wife ‘why are you giving 
me this much food I don’t need it’. 
Gerald: yes yes I get this on Sunday you know, five veg, one 
potato and the meat, and I say why is it five veg? I say chop it in 
half that’s too much for me. 
Gerald’s experience challenges current UK guidelines for long term incretin use 
CG87 (NICE 2009) and NICE diabetes pathway (2012), which recommend 
withdrawal of incretin therapy if 3% weight loss and glycaemic targets are not 
met within six months. Conversely Bob connects an improvement in his 
glycaemic control with the ability to recognize the satiety triggers which then 
triggered weight loss: 
...weight never came off until my HbA1c came below 6. Now I’m 
down to 5.2 and the weight is just falling off. Because to me that’s 
when the appetite suppressant in Byetta started to work for me ... 
but it was noticeable that I didn’t want the evening meals. 
4.2.2 Changes in behaviour 
Another of the study aims was to explore what changes people made in their 
eating patterns or food choices in response to GLP-1 treatment and any 
strategies they had developed to avoid side effects of medication. The 
participants had all found it hard to follow the currently accepted healthy eating 
guidelines (Diabetes UK 2012; NICE 2012, 2008) until starting GLP-1. 
Smaller portions 
Many authors attribute increasing portions sizes of energy dense foods against 
a background of reduced activity to be the major contributing factor to 
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increasing obesity and associated T2D (Sharp and Sobal 2012; van Kleef et al 
2012; Chandon and Wansink 2007; Ello-Martin et al 2005; Diliberti et al 2004; 
Mitchell 1999). GLP-1 therapy has helped participants in all three groups reduce 
portion sizes. Johnny explained how he achieved this at home and Linda 
agreed that portion sizes are important: 
I changed my dinner plate sizes. .. I went down to a smaller bread 
and butter plate. It’s much smaller and it looks nice and full but the 
portions are half of what would be on a normal dinner plate, it 
works though portion control is the answer to most of it I think. 
Laura also mentioned she had changed her plate size, which makes her meal 
appear more palatable but the thread was not picked up by anyone else in g2: 
I swapped my plates, I only have a plate about that big now, a side 
you see it on a smaller plate, it looks enough, a lot, yes if I have a 
meal or something like that I just put it on a small plate and that’s 
my plate now. 
Although larger cereal bowls and wine glasses have been shown to increase 
consumption (Sharp and Sobal 2012; van Kleef et al 2012; Sobal and Wansink 
2007) research has not confirmed this effect with plates (Rolls et al 2007). It is 
of interest therefore that Johnny, Laura and Linda, reduced plate size after 
starting GLP-1 treatment as a response to smaller meals rather than as an aide 
to reducing portions, commenting that their food looks better on a full plate. 
Gwen spoke for Lionel highlighting that he eats much smaller portions: 
... portion control is far better now. He knows when he’s full when 
he’s had enough whereas a year ago he could eat a massive 
great plate full now he’ll only eat half of that amount. 
Maud and Bert a retired couple also found they were eating smaller meals, 
Maud spoke while Bert nodded affirmation: 
I find that smaller meals are the answer, and if I don’t want it I’ll 
just leave it. 
Adam explained when he prepares his own food he has a smaller potion:  
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... I’ll have a small sandwich and I’ve started doing things like 
making a sandwich with one slice of bread instead of two, so half 
a sandwich and I find that is normally plenty. 
He contrasts this with perceived portion size when eating outside the home and 
acknowledges that he is recognising cues to eat less but returns to his difficulty 
in achieving this in a social setting:  
..if you go somewhere, ... you say no I’ll just have sandwich they 
will automatically do four slices and make it four, two sandwiches 
because that to most people is seen as a portion of sandwich. So 
that’s the way I find it that really it’s encouraging me to want to eat 
less although actually eating less is not as easy as it ought to be. 
Rolls and colleagues (2004) investigated varying sandwich size and energy 
levels to study satiety. Other researchers have linked increasing portion sizes 
and energy density to obesity (Ello-Martin et al 2005; Ledikwe et al 2005; Young 
and Nestle 2002). 
Reduced cravings and grazing 
Craving is an intense desire to eat specific foods and is often thought to be 
linked with dietary restriction, poor dietary compliance and frequent snacking 
(Pelchat 2002; Weingarten and Elston 1990). Recent studies have shown food 
cravings to be associated with active dieters (Massey and Hill 2012), higher BMI 
in the Diabetes Prevention Trial (DPP) and more common in younger people 
(Delahanty et al 2002). Several participants commented they had noticed a 
positive reduction in food cravings or grazing behaviour since starting GLP-1. 
Linda commented: 
I haven’t craved anything .. I very rarely now touch chocolate and 
that’s not because I think oh that’s bad for me, because I’d have 
eaten it regardless. ... I was terrible for chocolate and crisps, really 
bad and there can be crisps in my cupboard now for, well till 
they’re eaten by somebody else ...and I don’t crave the chocolate. 
This prompted others in g3 to talk of their previous love of chocolate and how 
much they could eat, Cath started: 
54 
I used to be a chocoholic, I used to eat Galaxy and there was 
always a Galaxy in my fridge always, and I’d take it out a whole 
slice [row] and I’d sit and eat it watching telly. 
The conversation evolved as a competition, with Linda stressing she would 
easily eat a whole family bar and Luke boasting that he used to eat two. Adam 
preferred packets of sweets but could now make them last longer. These 
accounts are in concordance with reports that chocolate, savoury snacks and 
energy dense foods are the most commonly craved foods (Massey and Hill 
2012; Rogers and Smit 2000). McVay and colleagues (2012) suggest that 
cravings are more common in women or limited to younger age group, yet the 
discussions of cravings within these groups were distributed across gender and 
age range. Mavis one of the older participants cited an example of buying 
unsuitable foods on impulse after an evening out for a drink with friends, 
however she is now able to resist eating them: 
..... in the morning I open my fridge and there’s a big strawberry 
gateau ...I’ve gone into the shop.  All these things I know that I 
can’t have up here and I’ve looked and I thought why did I do it?  
Where the hell did this come from ... I’ve had to ditch it because ... 
I know if it was there too long I could look at it for so long. 
Mavis attributes this self-control to her GLP-1 treatment however, previous 
diabetes education and dietetic support could also explain her restraint as 
weight management programmes have been found to assist people in resisting 
cravings (Massey and Hill 2012; Gilhooly et al 2007). Not all the participants 
recognised food cravings, but there was a general consensus that they had 
reduced between meal snacking or ‘grazing’ especially in the evenings. 
Speed of eating 
It has been argued that our fast food culture, the demise of family meals and 
trends towards eating ‘on the hoof’ have contributed to the obesity epidemic. In 
France policy makers have reversed the obesity trend by promoting the use of 
locally grown produce in schools. French family style eating is encouraged with 
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long lunch breaks and traditional three courses rather than fast foods consumed 
sitting around table (Bertin et al 2012; Dubuisson et al 2010; Rozin 2005). 
Research has shown a positive association between eating quickly and 
increased body weight (Maruyama et al 2008), an independent association with 
insulin resistance (Otsuka et al 2008) and more recent work has linked this with 
T2D (Saito et al 2012). Discussions around changes in speed of eating 
occurred in each of the three groups with participants commenting that they 
were eating more slowly since starting GLP-1 treatment. Mavis raised the topic 
by asking if it was coincidental that she eating more slowly, all in g2 recognised 
this association. 
Mavis: Is it coincidence since I’ve been on this drug that um my 
speed of eating has gone to minimal?  
Bob: Slow, I’m the same. 
Mavis: ... and it never was ... I cannot believe how long I’m just, 
just, into my meal and my daughter’s taking the plate away.  
Laura: I thought that was just me eat slow … my partner finishes 
his and I’m still eating mine and he has more. 
Bob: I’m always last to finish…whether I eat at home, eat out, eat 
in a restaurant or whatever, I’m always last to finish. 
Gerald: Yea I’m the longest to eat in my house. 
Lionel: I’m always last. 
Adam and Maud had also noticed a change and Bert agreed but Betty thought 
she ate normally whilst Ruth was not sure about speed of eating, she thought it 
was related to lack of appetite: 
Adam: Yes, yes, I’m often the last to finish now which I never used 
to be. As a child I was always told nobody is going to take it away 
from you  don’t eat so quickly and now, …  but I still do that um but 
I’m yes eating more slowly…I almost always used to be first and 
now I’m last. 
Maud: Yes, I eat slow anyway. I’m always last to finish, yes no 
matter how big me portion is I’m always last to finish.  
Ruth: I find I don’t really get hungry as such until the evening 
really. 
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Ruth’s thoughts that lack of appetite contributed to speed of eating were 
mirrored in an exchange in g3. Cath suggested not having an appetite for food 
and eating more slowly impacted on the portion size, Linda endorsed this with 
frequent interjections and non verbal signals. However, for Mark conventions of 
social eating posed difficulties, if he was satiated ahead of other diners with 
food still on his plate, he would move food around thus he appeared to be 
eating slowly. Luke did not agree that he ate any slower: 
Cath: Well I think because I’m not hungry I’m not eating so fast 
anyway and I think that’s another contributing factor, the fact that 
you can’t finish what’s on your plate, because if you eat slower 
anyway and you haven’t particularly got the appetite for it in the 
end you say ‘I’ve had enough of that’ and you give up don’t you?. 
Mark: Only that sometimes you’re getting towards, if you’re out for 
a meal, you’ve sort of reaching your limit and you start pushing it 
round a bit because everybody else is still eating ... not 
necessarily eating slower but as I say at that stage you don’t want 
to eat you can’t but you don’t want to just put your knife and fork 
down. But I don’t think I eat any slower. 
Roz: What about you Luke have you noticed a change? 
Luke: If anything I eat quicker  
Roz: You eat quicker? 
Luke: Yeah ... yeah then, of course, I can’t finish it.  
This link between speed of eating, satiety and anorexigenic gut hormone 
response has been confirmed by Kokkinos and colleagues (2010) who found 
that eating at a moderate pace has a greater effect on satiety but not hunger, 
whilst a study retraining obese adolescents to eat at a normal pace reduced 
weight and had a significant impact on the gastrointestinal hormone response to 
food (Galhardo et al 2011). The experiences related by participants that this 
dissertation is based on afford some insight into the differing effects of GLP-1 
analogues on satiety and hunger.  
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Mark commented on a positive effect of GLP-1 treatment, he has more 
enjoyment of food because he is not eating just to satisfy his physical hunger: 
Mark: I think I enjoy my food more now, because previously I was 
just hungry and it didn’t matter what it was I had to eat. Now I feel 
‘Oh I could quite fancy that tonight,’ perhaps it’s because... I’ve 
been picking and choosing. Whereas if that had been twelve 
months ago. We’ll have to have something for tea, I’d have just 
looked at what was on the shelf and thought that’ll do!  
Lowe and Butryn (2007) distinguish eating for pleasure which they term hedonic 
hunger as opposed to eating to satisfy a physical need. Others in the group 
especially Linda endorsed this change from a compulsion to eat because of 
physical need with verbal and non verbal signs. Mark reflected that he felt this 
was a positive change: 
... but I think now I stop and think more carefully about what we’re 
going to eat and I think we could have a bit of that and that’d be 
nice or I could just fancy that. I hadn’t really thought of it before but 
now I do actually pick and chose a lot more about what I eat and 
what I don’t eat.  
The remark from Mark also illustrates how the nature of the group discussions 
appeared to enable participants to both recognise and articulate their 
experience of how their eating habits had changed after starting GLP-1 
treatment.  
4.3 The Medical Experience 
This theme encompasses contributions relating to practical and medical aspects 
of GLP-1 treatment, glycaemic control, medications and side effects. 
4.3.1 Medications  
Polyphamacy for treatment of diabetes, to prevent or ameliorate complications 
and concomitant conditions is common in diabetes management (UKPDS Study 
Group 1999). For many of the participants a major benefit of starting GLP-1 
treatment was not only improving glycaemic control and losing weight but being 
able to reduce their other medications, all of which have potential side effects 
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(Campbell 2011; Barnett et al 2007; Bailey 2000). The participants linked their 
experience of GLP-1 treatment with their day to day management of living with 
diabetes confirming Anderson and Funnel’s (2010, p.278) assertion that not 
only do people living with diabetes provide 98% of their own care but that:  
The greatest impact on the patient’s health and well-being is a 
result of their self-management decisions/actions during the 
routine conduct of their daily life.... Diabetes is so woven into the 
fabric of the patient’s life that many, if not most, of the routines of 
daily living affect and are affected by diabetes and its self-
management.  
Johnny exemplifies this when he discussing his blood sugar readings: 
..they were up a little bit last year because of the surgery ...I 
doctored the medication myself by adding the gliclazide with the 
metformin, ... that combination is spot on, no hypos, no feelings of 
having a hypo, .... My sugars can go as low as 4.5 which is great 
when my sugars are measuring like that I feel great, I’m so full of 
energy I can’t stop. 
Johnny’s comment reinforces the significance for individuals and their 
healthcare advisors of managing or avoiding hypoglycaemia. It is a common 
limiting factor in achieving good glycaemic control (Bailey and Day 2010; Amiel 
et al 2008) and has a significant impact on quality of life and self management 
but can be overlooked in T2D (Barendse 2012; Farmer et al 2011). 
Side effects of diabetes medication 
Several participants reported nausea and vomiting associated GPL-1 treatment 
particularly in the beginning but all felt it worthwhile persevering as symptoms 
subside over time. Johnny and Ruth had been changed from exenatide to 
liraglutide and found the vomiting improved. Bob and Lionel felt eating too much 
could trigger nausea or vomiting: 
Bob: I do feel nauseous sometimes in the morning.  I’ve been 
physically sick twice and that was purely from eating too much. 
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Cath described a background of nausea but had found a ginger biscuit could 
help and Johnny found dry cream crackers also helped and were not so sweet, 
Linda reported the nausea was similar to morning sickness of pregnancy:  
That’s how the sickness is with me you know and I have had 
morning sickness you know, that’s what it feels like that morning 
sickness feeling ... ‘Well it’s not every single day, it’s not all the 
time, but the majority of it is, … but then it’s ‘Oh my God’ that 
sickness thing … there’s no pattern of it triggering. 
Linda who had the least experience with GLP-1 treatment (three months) and of 
living with T2D (four years) was still struggling to recognize a pattern. She felt 
pain killers for a back injury and anti-hypertensive medication made her nausea 
worse. However, as the discussion continued she acknowledged that fatty foods 
and portion size were contributing factors. Betty, Maud, Bert, Gerald with three 
to four years GLP-1 use and Mavis seventeen months use were not affected by 
nausea. Mark found leaving a gap between his exenatide and other medications 
lessened his nausea: 
I’ve found the way for me, to deal with that I take my insulin and 
exenatide and then about 20 minutes later I take the rest of my 
medication then I move onto the food after that. ... I found by 
breaking the medications up into two lots that’s ... sort of stopped 
that nausea.  
Mark found a really positive benefit of exenatide, was that he rediscovered 
clarity of thinking and an ability to concentrate: 
When I was on insulin I found, what I describe as hard thinking 
impossible, I couldn’t concentrate, I couldn’t really think in straight 
lines once I got onto exenatide, within days it was like a fog lifted I 
could think, I could do things, I could plan things which I hadn’t 
been able to do and that was liberating in all kinds of ways and for 
me it’s, just sort of, changed my life from being ‘Oh I’m a diabetic’ 
to suddenly I can do things and it’s been absolutely brilliant for me. 
This effect disappeared when Mark changed to liraglutide but returned when he 
changed back to exenatide. Betty also thought she felt brighter and more alert 
after she started exenatide however, none of the other participants mentioned 
improved cognition although Johnny nodded in agreement.  
60 
An association between cognitive dysfunction and diabetes has been 
recognised, with hypo and hyperglycaemia, micro and macro vascular 
complications, vascular risk factors, depression and genetic factors all being 
implicated as contributing to impaired cognition (Blaak et al 2012; Reijmer et al 
2010). Studies of effects of improving glycaemic control have demonstrated 
improved memory (Ryan et al 2006; Mussell et al 2004), whilst animal studies 
with GLP-1 analogues have shown improved learning and memory (Hamilton et 
al 2011; Isacson et al 2011; Abbas et al 2009), there is a paucity of evidence 
addressing this issue in humans. Lerche and colleagues (2008) postulated that 
GLP-1 may limit variations in intracerebral glucose thus providing a neuro-
protective effect, these mechanisms are currently being investigated in trials of 
neurodegenerative and cerebrovascular disorders (Salcedo et al 2012). 
Although liraglutide studies showed improved quality of life there was no 
significant improvement in cognitive functioning which could not be explained by 
improved glycaemia (Bode et al 2010).  
In UK clinical practice GLP-1 treatment is added in addition to metformin, 
sulphonylurea and increasingly insulin. If improved glycaemic control is 
achieved with GLP-1 treatments the other medications maybe reduced or 
stopped (Barnett 2011; Thong et al 2011; NICE 2009). As part of their 
discussion of side effects several participants referred to other diabetes 
medication particularly metformin and insulin, there is not space within this 
report to explore these in depth. However, I provide some examples as they 
elucidate the lived experience of incorporating GLP-1 therapy into the treatment 
pathway and a personal perspective of balancing iatrogenic effects versus 
benefit. The revelations provide fresh insight into the daily aspects of living with 
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diabetes and integrating medications and lifestyle changes into everyday 
routines (Cobden et al 2010; Handley et al 2010). 
As described in Chapter 2 metformin is recommended as first line medication in 
T2D, nausea and diarrhoea are recognised side effects particularly if not taken 
with food (Donnelly et al 2009b). Several participants expressed acute physical 
and social distress as a result of these gastro-intestinal disturbances, they were 
relieved to be able to reduce metformin after the introduction of GLP-1: 
Mavis: I’ve been down in the middle of town and get this pain and 
sometimes if you can’t get to a toilet you are in trouble.  I mean I 
had the sweat just dripped off me with pain and anxiety trying to 
get somewhere safe ...and it just goes on until you say I can’t 
stand it ...  Because I get these cramps ... the pain is unbelievable 
… with Metformin. 
A referral to secondary care for medication review and initiation of GLP-1 
treatment helped Mavis and Cath: 
Mavis: I was on 2000 a day [of metformin] and he cut it to 1000, 
which is one in the morning 500 and 500 in the evening…I 
dropped 500 and just take the morning one and the pains have 
gone. 
Cath: Well I started off on metformin when I was first diagnosed, 
but I had awful problems with it, the ordinary metformin. It just 
made me sick ... I couldn’t even go out for a walk, cos usually I 
needed the loo, I was just in an awful state so the doctor sent me 
to hospital [secondary referral] and the consultant suggested that I 
try exenatide and that was literally brilliant. 
Although gastrointestinal symptoms of metformin are known, the severity varies 
from mild disturbance which can be managed with dose titration or change to a 
slow release formulation, to the extreme symptoms described here. Mark 
described the work and social consequences of these symptoms and a change 
to insulin by his GP did not help: 
When I started on metformin I had it bad, I couldn’t go to work, I 
didn’t dare go to work, I was throwing up I was rushing to the toilet 
for several weeks and that’s why I got moved onto insulin fairly 
quickly. But ... I didn’t lose the hunger, even though I was throwing 
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up and rushing to the loo I still felt hungry, I felt even hungrier in 
fact.  
Despite feeling so ill, Mark still experienced hunger until he started exenatide: 
Everybody was saying to me ... ‘stop eating and stop being sick’ 
but I thought I’m hungry, I’m starving that was really, really 
horrible. But I didn’t have that with Byetta, the exenatide. I felt a 
little bit if nausea but  ... when I hit on the idea of spreading them 
out ... I found it was better. 
When treatment with diet and oral agents for T2D fail the addition of insulin is 
recommended (NICE 2012). However, as discussed in 2.2.4 this can be 
associated with a spiral of increased weight gain, worsening control (Holman et 
al 2008, 2007) and for some individuals a real sense of lack of control and 
failure as described in the examples below by Mavis, Johnny and particularly 
Mark. Mavis, a petite 73 year old was distressed by the weight gain associated 
with starting insulin and lack of improvement in glycaemic control:  
Mavis: ...because I was really out of control on the insulin it was 
almost as though I’d gone allergic to it. It was having no effect what 
so ever I was climbing 17, 18, 19, 26 [home blood glucose readings] 
and I was flashing ketones which ... I know was bad ... I went up to 
thirteen stone and now I’ve dropped down to ten, ten twelve [10st 12 
lb] or something like that that. 
Her home blood glucose readings are now between five and seven m/mols/l, 
she reported a recent discussion with her family doctor: 
He said ‘blood pressure perfect, cholesterol perfect, weight, 
perfect’.  you know he said to me ‘I can’t believe the readings’.  
Johnny and Mark in a different group from Mavis echoed her relief once starting 
GLP-1 treatment when they discussed their problems associated with insulin. 
Johnny: ... that’s when I went on insulin, then of course that’s a 
snowball from hell ... just kept spiralling, I kept upping my insulin I 
was taking because my sugars weren’t under control, … This 
doesn’t work it makes it worse, the weight just keeps going on and 
that’s when we decided I’d go on the exenatide. I crashed the 
weight down and I came off the insulin. 
Mark: You’ve touched on something else there; you totally feel in 
control, because what I was feeling before with just the insulin and 
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the metformin was I wasn’t in control, I still needed more of it and 
I’d still feel tired, I’d still be hungry all the time.  
Johnny: ... you wanted to sleep all the time? 
Mark: Yea and you’re not in control of yourself, these things are 
happening. Once I got onto exenatide, suddenly you’re in control, I 
can regulate it, I can decide am I going to take 15 or 20 units.  
Roz: Of your insulin? 
Mark: Yes, I can do that and I feel I’m in charge of my life it’s not 
this wretched stuff that I’m sticking into myself and that’s been a 
good feeling. 
Worsening control or poor disease outcomes are often attributed to non-
compliance or non-adherence to prescribed treatment in chronic disease 
management, especially diabetes. These examples of physical, social and 
psychological distress associated with previous medication, relieved by 
changes in treatment regimes illustrate the importance of listening to the person 
living with a condition (Cobden et al 2010; Handley et al 2010; Williams et al 
2009; Kripalani et al 2007). 
4.3.2 Management of glycaemia 
When discussing their improved glycaemic control on GLP-1 treatment the 
participants referred to blood glucose or sugar levels as well as HbA1c, most 
were aware of the implications of the results and some were confident adjusting 
their medication or lifestyle in response to their self monitoring of blood glucose 
(SMBG) readings. Mark and Johnny explained that they tested either to check 
to avoid hypos if they were not feeling well or to verify the effect of an unusual 
meal: 
Mark: I tend to take it if I’m feeling a bit odd or a bit off colour or if 
we’ve been out for a meal, something like that when I don’t know 
how much of anything is in there. It’s only on those occasions I’d 
take it. 
Johnny: ...when I don’t feel spot ... I’ll test ... nine times out of ten 
it’s OK but I test when we have been out for a meal 2 or 3 hours 
after I’ve had my meal because that’s what gives you a more 
accurate reading what you’ve been taking in. 
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Their use of monitoring complies with recommendations by NICE CG87 (NICE 
2009) for self monitoring of plasma glucose (SMPG). Rising costs of increased 
incidence of diabetes have led to an evaluation of cost effectiveness of SMBG 
and some restriction of diabetes testing strips, particularly in insulin naive 
individuals (Benhalima and Mathieu 2012; Poolsup et al 2009; Towfigh et al 
2008). However, Fisher, Polonsky and colleagues (2012; 2011, 2010) 
demonstrated that educating both patient and clinician to test in a structured 
episodic manner can reduce costs whilst also improving clinical outcomes. 
Linda reported that she lost motivation after her GP told her to stop testing her 
blood sugars and offered no dietary support:  
I was really good and I was doing my bloods all the time but the 
worse thing they ever said at my surgery was “there isn’t a 
diabetic diet you can have everything you want within a reason 
and don’t take your bloods”. So ... it went downhill I thought ... I 
can eat that ...I don’t have to worry about my bloods, because 
when I was taking my bloods it made me more aware and I’d think 
actually I’d better not have that bar of chocolate because 
otherwise .. I was better doing that ... it made me more aware that 
I was diabetic, but when I stopped that I crept back to where I was 
before. I’d just eat anything and whatever, didn’t really think about 
it.  
Cath also reported that her GP had told her she was not allowed to test and she 
now feels disempowered.  
4.4 Social, Cultural and Emotional Influences 
Delormier (2009) and Crotty (1993) express concern that the science of nutrition 
and policies to address dietary change too often overlook the social, 
behavioural and cultural aspects of food. Crotty (1993, p.109) suggests that: 
... the act of swallowing divides nutrition’s “two cultures”, the post 
swallowing world of biology, physiology, biochemistry and 
pathology, and the pre-swallowing domain of behaviour, culture, 
society and experience. 
In sections 4.2 and 4.3 I have explored contributions mainly describing practical 
and physical aspects of diabetes, medications and eating or the post swallowing 
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culture. In this section I include comments from participants which elucidate the 
latter domain. 
4.4.1 Emotional and social aspect of living with diabetes 
The participants chose to describe significant stages of their diabetes journey to 
add context to their current experience. I provide a brief selection from many 
that illustrate how diabetes is woven into all aspects of their individual life and 
relationships (Anderson and Funnell 2010; Davies 2010).  
Impact of diagnosis and symptoms  
Reactions to a diagnosis of diabetes are variable with many individuals adapting 
quickly, others are relieved there is explanation for recent ill health, whilst some 
experience shock and distress (Vermeire et al 2007; Snoek and Skinner 2006; 
Peel et al 2004; Pibernik-Okanović et al 1996). Davies (2010, p.607) highlights 
that whilst coping with the ‘lifestyle and intellectual challenges’ of a new 
diagnosis, they must also come to terms ‘the emotional consequences of being 
diagnosed and living with a chronic, progressive condition’. Studies have shown 
an increased incidence of psychological ill-health with a two to four fold increase 
in depression (Davies 2010; Ali et al 2006), whilst Fisher and colleagues (2012; 
2010) have highlighted that DD is in its self an added burden. Within this study 
Cath, Linda, and Mark described the effect of diagnosis and associated 
symptoms on their lives, these highlight the emotional distress and social 
impact of diabetes: 
Cath: ... sleeping all the time it was dreadful, dreadful. When my 
diabetes first started I was on that metformin and it was just, life 
was miserable, it really was miserable. 
Linda: When my diabetes first started my kids would say ‘Mum 
you are so lazy why are you going to bed all the time?’ and I’d say 
‘I cannot, I can’t literally, I cannot physically stay awake’, and for a 
couple of hours I was out literally out solid. 
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The value of family support adapting to diabetes, integrating and maintaining 
lifestyle changes is well documented (Franks et al 2012; Gunn et al 2012; 
Vermeire et al 2007). Linda felt unsupported and distressed that her children 
were critical when she was too tired to cope and her mother unsympathetic:  
‘Well you’re never going to sleep tonight’ my Mum would say to 
me, ... well I’m awful, useless, I literally could not stay awake it 
was, I’ve got to go, I’ve got to go to bed.  
Like Linda, Mark described that his family and friends were critical and did not 
understand his hunger or exhaustion and Johnny explained that his long term 
partner, despite being supportive had trouble understanding: 
Mark: I was feeling hungry when I got up and people would say 
‘what are you doing? You’re eating too much you’re sleeping all 
the time, you need to stop this’. 
Linda: Yes, I don’t think they understand.  
Johnny: No, they don’t, they don’t. My partner even though he’s 
gone through all this diabetic stuff with me for the last ten years he 
still has trouble sometimes understanding the problems that come 
with it. 
Despite these negative examples focusing on of lack of understanding, there 
are positive examples of support from partners and family throughout this study. 
Mavis’ daughter, a nurse, regularly visits her and discusses her diabetes 
management and Betty’s carer oversees her overall care. Maud and Gerry have 
taken charge of managing dietary changes for themselves and their respective 
partners Bert and Les:  
Maud: When we go out I’ll ask for a child’s meal ... that’s quite 
satisfactory. 
Bert: ...same I do as well. 
Gerry: I’ve stopped ... grazing. It’s me I’m the food police really. 
Lewis and Alan’s wives cook and serve meals but need to be reminded to serve 
them smaller portions, whilst Adam’s wife a diabetes nurse, always has glucose 
tablets ready for him. 
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My wife keeps looking at the expiry dates ... .if I’ve not got any 
she’s got some to hand. ... Having been a diabetes nurse she’s 
conscious of these things and carries them about. 
Realising the severity of diabetes 
Adam remembered that adding in GLP-1 injections was an important milestone 
alerting him to the severity of diabetes and that he felt a failure. 
..when we first went on ... exenatide ...psychologically I was pretty 
depressed for a bit that I was now having to do two injections a 
day... once you are so ill that ... need to keep having injections 
that’s a failure  
This sense of failure linked to requiring injections to control his diabetes has 
been recognised by many authors investigating barriers to insulin initiation and 
improved diabetes care (Ratanawongsa et al 2012; Karter et al 2010; Larkin et 
al 2008; Meece 2006). This reluctance by both HCP’s and their patients to 
initiate insulin has been called ‘Psychological Insulin Resistance’ (PIR) 
(Woudenberg et al 2012; Wang and Yeh 2012; Polonsky 2007b; Polonsky et al 
2005). Yet Linda felt that starting injections made her accept her diagnosis:  
I know I’m diabetic but because I’ve had high blood pressure since 
I was 25 and I’ve taken all these pills, so you’re early diabetic, OK 
just take another couple of pills, not really being that aware of the 
fact I was. … I don’t even really think about it.... starting on the 
injection it sort of makes you realise yes I have got it. 
Mark recounted an incident also requiring injections that prompted his 
acceptance of the severity of his diagnosis: 
I think when it came to me, I grazed my leg …I stepped back into 
a wall and I grazed it ... never thought anything of it. The next 
night my leg felt like it was one fire, so I went to a pharmacy to get 
some antiseptic cream … Fortunately the young lady who was on 
counter said ‘can I see it, make sure there’s nothing wrong?’ she 
looked at it and said ‘get to hospital now, don’t go home, go to 
hospital and see about it’.  
Although shocked at her reaction he was relieved that this prompt advice and 
subsequent treatment saved his leg: 
I spent six weeks on antibiotics injections and all sorts of things 
getting it sorted, and they said it’s because you are diabetic you 
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are get infections much quicker and more severe, it really woke 
me up to the fact that I was a diabetic.  
Working life 
Lack of control at work, low status jobs and shift work or irregular hours have 
been shown to impact on health status and the ability to make healthy lifestyle 
choices (Smith and Holm 2010; Bisogni et al 2005; Devine 2005; Smith and 
Hart 2002). For people living with diabetes integrating diabetes management 
including pre-meal injections, tablets with food and SMBG into their life style 
whilst also making appropriate food choices adds an extra complexity 
(Anderson and Funnell 2010; Polonsky et al 2010). Although socio-economic 
status was not noted within this study comments by the participants who 
highlight these work stresses follow this pattern. Linda a community carer, 
Laura a school cook and Bob a paramedic all mention difficulties managing their 
diabetes associated with their work: 
Linda: That’s when I find it’s a problem for me, because I do care 
in the community and if I don’t eat earlier in the evening rather 
than later it’s hopeless that’s when I’m really sick and it’s a 
nightmare the later you go into the evening the worse it gets. 
Laura: It is sometimes because like at school you’ve only got 
quarter of an hour to have dinner.  I find it very difficult, you want 
to get on, you want to eat it as fast as you can and that when you 
do that you eat slightly more.  
Bob: I had to tell DVLA ... I was put on the insulin and they just 
took all my licenses away completely, except for my ordinary basic 
car license which is no good to my job. 
Being able to transfer to GLP-1 treatment in place of insulin allowed Bob to 
regain the licences he needed for his work: 
I went back to the DVLA ...said I am now on exenatide ... they just 
gave it me it all back again. 
Adam and Mark, both professionals spoke of the unpredictability but also of 
autonomy within their work. Mark has integrated his medication routine into his 
morning work routine:  
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I take my insulin and exenatide and then about 20 minutes later I 
take the rest of my medication then I move onto the food ... that’s 
... stopped that nausea... I go and do my emails or a phone calls 
or something in that time. 
The other participants some of whom were retired did not mention any conflicts 
with work and diabetes. 
4.4.3 Cultural influences 
Eating patterns, portion sizes and norms are thought to be established early in 
life (Delaney and McCarthy 2011; Wethington and Johnson-Askew 2009; 
Devine 2005; Herman and Polivy 2005). Family meal experiences were shaped 
by food shortages and rationing associated World War II, 12 of the 15 
participants were born between 1930’s to early 1950’s. Delaney and McCarthy 
(2011) assert that ‘foundations of enduring dietary habits have been firmly set in 
childhood’ (Delaney and McCarthy 2011, p.117), Adam encapsulates this when 
he described a deeply entrenched attitude to food and food waste which he 
attributes to his childhood experience during 1940’s and rationing: 
...as a child in the forties I suppose food was precious and I was 
always brought up to eat everything that was there...you wouldn’t 
want to throw them away... that’s a cultural thing that I still find 
very hard to change.  If somebody dishes me up a plateful of food 
culturally it’s my job to eat it. 
Ruth: I’m a bit like you I tend to think...I’ve got it so I have to eat it. 
Cath although in her 60’s felt guilty that she was no longer able to follow her 
mother’s advice to eat a ‘good’ meal: 
My Mum always used to say ‘you’ve got to have a good breakfast’, 
and ‘you’ve got to have a good lunch’ and ‘you’ve got to have a 
good dinner’ and when you can’t eat it you feel guilty. 
Cath did not define a ‘good meal’ but from the context and later comments it 
may be a substantial hot meal eaten sitting at table, analogous to a ‘proper 
meal’ described by several authors (Bisogni et al 2005; Marshall and Anderson 
2002; Murcott 1982). Cath describes what she can eat since starting GLP-1 
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treatment, recognising she is making healthy choices but for her it is not a 
‘proper meal’: 
I can still eat fruit ... but I come to lunchtime and I can’t even 
manage 2 slices of bread and butter with something in the middle 
as a sandwich, the exenatide has taken my appetite away and I 
can’t even manage that. ...I’ll think what am I going to have for 
dinner?’ ... I’m not hungry I can’t eat anything so very often I’ll end 
up with scrambled egg on toast or piece of bacon on toast ... 
whereas before I would sit and eat a proper meal for my dinner, 
now it’s, it’s ... picking when you feel hungry. 
Johnny comments that he has returned to sitting down to eat at a table draws 
on this concept that ‘a proper meal’ involves eating at a table: 
I always make a point of sit at the table to eat, I don’t carry it in like 
I used to ...  and watch telly and eat off my lap. I sit down at the 
dinner table every day for evening meal and for breakfast. 
For all of the participants this conflict between their accustomed norms, whether 
portion size, speed of eating or not wasting food, and changes since starting 
GLP-1 was evident. Adam concludes his thoughts on food waste with the 
following: 
... a cultural thing that I still find very hard to change.... I always 
feel that my host or hostess would be very hurt if I didn’t eat all of 
the food that had been lovingly prepared. 
This contrast is highlighted when Adam, explains that he would previously eat 
two meals if social politeness demanded: 
...sometimes I would have a meal, go somewhere not realising 
that I was going to be fed and then simply perfectly happily eat the 
meal that was provided by a friend because it would be impolite 
not to... I might struggle with that now.  
4.4.3 Emotional and Social aspects of eating and food 
Eating and food choices are part of everyday activities in the home, at work and 
within relationships (Delormier et al 2009). The participants described the 
impact of their changes in appetite on family meals and social occasions. Luke 
reported his wife’s concern when he cannot finish his meal: 
Luke: I can’t finish it and the Missus says ‘you’re not hungry any 
more, you feel full up?’ and I just say ‘yeah’ 
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Roz: Do you find that difficult that your Missus is perhaps a bit 
offended or upset?  
Luke: Yea, she makes my favourite cottage pie ... big dish and we 
have like half each with a bit of veg and I can no longer eat it and 
she gets a bit upset. But I say ‘don’t worry about it I’ll have it 
another time’ and of course it comes to that other time and I don’t 
want it because I’m not hungry. 
Linda described tensions when her husband, a fisherman, returns from sea as 
he likes to take her out for a meal, but she worries the portions will be too big for 
her and cannot enjoy the occasion: 
I find it’s a shame if we go out for a meal. ... there’s no way I’m 
going to eat I know when the portions come out it’s going to about 
a quarter and it’s such a waste of money, I know I won’t be able to 
eat it. Because my husband’s a fisherman ... he’s away a lot and 
when he comes home he likes to take me out for a meal and ... I 
don’t want to go because what a waste of money. 
Others in the group suggested asking for a child’s portion or a starter as main 
course when eating out, but Linda was unsure whether she would feel able to 
do that. Linda is also experiencing extra stress with her daughter because of 
lack of interest in food:  
I find it hard, because it’s only me and my daughter because my 
husband’s away ... and we argue ... about what we are going to 
have, because she’s quite fussy any way ... neither of us will eat 
the same and I can’t be bothered to cook anyway because I don’t 
fancy it. 
Ruth and Cath mirror Linda’s difficulty to motivate themselves to prepare food 
just for one:  
Linda: Actually It wouldn’t bother me if I didn’t have anything at all. 
Cath: I’m just the same. 
Biscogni and colleagues (2002) highlight that people define themselves by their 
usual or preferred eating behaviours, a thread which has been evident in 
comments across all participants speaking of themselves as previously been 
known as ‘enjoying food’, ‘a good eater’, ‘someone who likes their food’. Bob 
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explained he warns friends who knew him as a ‘big eater’ that he now eats 
much less: 
When I go on away on holiday with friends ... one of them she’s a 
fabulous cook and you know I’ve said to her please don’t be 
offended but I just cannot take everything that you cook I will do 
my best. .. what she does now she puts it on the table and lets me 
help meself. 
Bob and Cath described that the change in their eating pattern causes concern 
amongst friends and family: 
Bob: When we first went there she would say that’s not enough for 
you.  Same as the wife, she would say you haven’t ate enough ... 
we didn’t have really big arguments but in the end I just said look 
forget what I’m eating concentrate on yourself.  
 Cath: ... the family come round and I cook a meal then I sit down 
with the family and I’ll have one little piece of potato, ... a few 
green beans and I might have a batter pudding and that’s all I 
have ... I do a roast dinner for the grandchildren and they say ‘Oh 
Nan what have you got on your plate?’ and I say well I can’t eat 
any more. 
Despite a trend towards more equality in food preparation (Aarseth and Olsen 
2008), participants in this study appear to conform to traditional gender roles of 
with women taking charge of the family diet and caring (Peel et al 2005; Charles 
1988; Murcott 1983, 1982). The women participants appear to be making 
adjustments to their own diet whilst balancing needs of their spouse and family 
whilst the men rely on their wives to organise the food, similar to other studies 
of gender roles in diabetes (Broom and Lenagh-Maguire 2010; Peel et al 2005). 
This is particularly evident when both in a couple have diabetes, the women 
manage their partners’ diet and diabetes. However, Mark is cooking while his 
wife unwell, Bob enjoys cooking special meals and Johnny does much of the 
food preparation in his relationship. 
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4.5 Summary 
The participants shared insights from their combined 148 years’ experience of 
living with T2D. The data demonstrates the complexity of the often 
subconscious balancing act of managing a chronic condition such as diabetes 
which impacts on every sphere of life. Returning to the two cultures divided by 
swallowing referred to by Crotty (1993), it appears from the contributions of 
these participants that the impact a medication which acts on the already 
altered satiety triggers of people living with T2D blurs these two cultures.  
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Chapter 5 Reflections 
5.1 Introduction 
In this final chapter I reflect on the research process, the findings and 
implications. Knowledge and evidence is acquired in incremental steps which 
feed into cycles of research, implementation and audit, generating further 
questions for research. Each significant step forward may have had numerous 
winding paths of earlier researchers contributing to fresh insights, not all of 
whom have been acknowledged. The evidence base for treatment and 
understanding of diabetes has developed and expanded over generations and 
across many disciplines. New treatments have provided hope and fresh insights 
into the mechanisms of diabetes but also new challenges and avenues for 
research. My research aim was to discover with a group of ‘expert patients’ 
successfully using GLP-1 treatment, whether their experience could inform how 
changes in appetite induced by GLP-1 treatment influence dietary choices and if 
they developed successful strategies to moderate side effects. 
5.2 Reflections on methods and methodology 
The earlier research leading to development and launch of this class of 
treatment defined the physiological mode of action and clinical outcomes in 
clinical trials. Quantitative measures of safety and efficacy in large comparison 
RCT’s are required by regulatory authorities to inform their decision but as 
Hardy (2009) suggests the personal narrative and the impact for an individual 
becomes lost in an aggregate of means. A qualitative research methodology 
enabled an exploration of the experience of some individuals who had 
participated in one such trial augmented by other participants more recently 
prescribed GLP-1 analogue treatment. 
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The purposive sampling strategy of individuals with successful experience of 
GLP-1 treatment for T2D yielded, by chance, a participant cohort representative 
in age, gender and ethnicity to the local population with T2D requiring triple 
therapy. The catchment area is a coastal and rural community dependent on 
tourism, farming, fishing and light industry, with a high percentage of retired 
residents. Although similar to many other coastal or rural areas, the cultural and 
ethnic mix is very different from that found in cities and many other regions of 
the UK. The results of the study should therefore be seen in the context that the 
focus groups were conducted in this particular location, time and place. Despite 
this, the insightful contributions from participants with a combined experience of 
37 years (448 months) of GLP-1 treatment use and 149 years living with 
diabetes may be applicable to a wider group. 
The choice to gather data using focus groups has been endorsed by many 
examples within the groups when contributions from one participant prompted 
others to reflect and share their own experience. Often, particularly when 
discussing the effects of GLP-1 analogue or insulin on appetite and eating, 
participants recognised as a revelation in another’s comments something they 
had not been able to articulate. Individual interviews could have afforded the 
opportunity to probe and ask for clarity at an individual level but the synergy and 
dynamism of the group interaction would have been missing. As highlighted in 
Chapter 3 the dynamics within each group were different, partly because of 
differing characters and the experiences they brought to the group and partly 
external forces described. Although group interaction is one of the strengths of 
focus group research, it can also be a disadvantage, as described in g2 (3.6). A 
combination of factors affected the power balance, group dynamics and 
facilitation of group discussions. It could be argued that if problems occur when 
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conducting individual interviews, only data collected on that occasion is 
affected, not a whole group. 
It has been valuable to reflect on this unintended example of how power and 
dynamics can be altered by a uniform, presence of a spouse or personal 
interactions, not only within the research context but also for clinical, work or 
social situations. When out of uniform, although participants in g1 and g3 knew I 
was a nurse, I was able to bounce questions addressed to me back to the 
group, explaining that they were the experts. I stressed my role as a researcher 
was merely to elicit and draw together any ‘gems of wisdom’ from their 
individual experience as the experts living with T2D and a new treatment. It is 
important to remember the symbolism and connotations engendered by a 
nurses’ uniform, so much part of our working life it is easy to overlook the 
impact on others. A nurses’ uniform can be seen as ‘... a nonverbal, conscious 
statement that nurses have the skills and knowledge to care for others’ 
(Spragley and Francis 2006, p.58). Although comforting to patients in an acute 
setting the uniform has been discarded in many other areas as it is perceived to 
be a barrier to establishing therapeutic relationships and inclined to foster the 
dependant patient role of a passive recipient of care (Arif 2012; Shaw and 
Timmons 2010; Sparrow 1991). Hospital uniforms reinforce hierarchical 
structures and can be seen as symbols of power and authority or of 
professional identity (Timmons and East 2011). Thus, as a nurse in uniform in 
g2, it was difficult for both the participants and myself to ignore the unspoken 
message of power and existing knowledge the uniform conveyed. Perhaps, my 
attempt to underplay my professional role to allow the group knowledge to 
emerge in g2 encouraged one of the participants to fill that authoritative 
vacuum. The group cohesion may also have been imbalanced by a spouse who 
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did not have personal experience of GLP-1 treatment, it is possible that the 
group perceived her be an ‘outsider’ without authority to comment (Allen 2004). 
The excellent quality audiovisual recordings endorsed the value of discrete 
modern recording equipment. All verbal and nonverbal interactions within the 
groups were captured electronically facilitating repeated observation of the 
subtleties of individual nonverbal reactions and group dynamics throughout the 
discussion to be integrated into the analysis. The richness this has added and 
potential for fuller analysis would recommend more widespread adoption in 
research of discrete digital audiovisual recording. Contrary to Al-Yateem’s 
(2012) findings, I found no reluctance to consent for recordings and discussions 
were very open. However, explicit permission for use of the visual data which is 
more difficult to anonymise, needs to be included in the consent process and 
consideration as to how this source data should be stored. The rapid 
development of high quality digital image capturing technology on smart phones 
and discrete devises offers potential opportunities for less obtrusive, or even 
covert data capture presents potential opportunities and challenges regarding 
confidentiality and consent (Cleland et al 2007). 
5.3 Reflections on the process 
 As described by Shepherd (2011) despite years of nursing experience, 
stepping into the world of social science research can make one feel a novice 
and challenges preconceived ideas. Designing the project, identifying and 
consenting participants then organising and conducting the focus groups, was 
similar to my clinical role. Listening to and watching the recordings to transcribe 
data, then immersing myself in data to code and analyse was initially daunting 
but as I have always been fascinated by peoples stories, I enjoyed the 
challenge. Exploring relevant literature from a broad range of sources and 
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disciplines to weave together the various threads into a coherent whole has 
been a revelation. 
The most demanding aspect has been finding a voice to write the thesis and 
maintaining the discipline of keeping to the task of writing. Part of my research 
nurse role has been to read and internalise clinical literature and study 
information to explain to potential participants and relatives in lay terminology, 
allowing the opportunity to ask questions or raise concerns. I recognise on 
reflection, that my method of gaining trust whilst eliciting the extent of 
background knowledge and preferred terminology has been to instinctively 
mirror opening conversations. I have found synthesising information from 
background reading of basic science, clinical research, diabetes, dietetics, 
sociology and psychology literature to write in the first person yet maintain an 
academic style has been a constant battle. My instinct being to mirror the style 
of the written evidence or to translate into lay terminology. The task of 
transformation from a clinical research nurse into a nurse researcher has been 
a fascinating journey.  
The individual participants reported having enjoyed being involved in the 
research project, to have learnt from talking to others in the group and 
expressed a hope that their experience would be useful. Several commented 
that, hearing others express symptoms or feelings similar to their own provided 
reassurance that they were not unusual. Advice and support was offered from 
within the group to avoid or alleviate symptom or problems. Many expressed a 
view that they felt valued that their opinions and ideas had been sought. 
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5.4 Implications for practice 
Just as effective self-management of diabetes or other chronic conditions 
requires integration with all aspects of the routines of daily living (Anderson and 
Funnell 2010; Forbes and While 2009), so also are food and eating woven into 
the social, cultural and emotional fabric of life (Delormier et al 2009). The 
incretin hormone based therapies for T2D provide new treatment options for 
T2D which improve glycaemic control without risk of hypoglycaemia or weight 
gain often associated with escalation of established T2D treatments. Individual 
responses to incretin based therapies have been varied, insights from this 
group of their successful adaptation to satiety clues may inform support and 
advice for other people prescribed GLP-1 treatment. 
5.4.1 Practical advice for individuals commencing incretin based therapies 
The shared experiences of the incretin response in T2D of the participants 
revealed common themes of potential value to others. 
 Perception of adequate meal size 
The enhanced satiety resulting from treatment often enabled participants 
to re-evaluate their habitual meal paradigm of an adequate portion size. 
Initially if these satiety clues were ignored, nausea followed. Many 
adapted to a smaller plate size at home, whilst in a social setting 
practical suggestions included requesting a child’s size meal or starter in 
restaurant or warning friends if eating socially outside the home. 
 Curtailment of the eating experience 
Slowing of gastric emptying and restoration of meal related satiety 
significantly altered both the duration of eating time and the number of 
courses which could be enjoyably consumed. Many participants no 
longer had puddings or snacks between meals, although some reported 
they were pleased to be able to act on healthy eating advice, others 
found difficulty adapting to these changes particularly in the family or 
social situations.  
 The social and emotional aspects of eating 
The potential beneficial effects of shared preparation and enjoyment of 
meals has been highlighted (Franks et al 2012; Delaney and McCarthy 
2011; Delormier et al 2009) and should not be underestimated. Amongst 
the fifteen participants the few who described the most difficulty adapting 
were women who were no longer preparing family meals or who were 
living alone. Some also described being disturbed that they were not 
eating what they perceived to be a ‘proper meal’. Persons living alone 
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may be disadvantaged by lack of social support adapting to the effects of 
GLP-1 based treatments. 
 Beneficial accessory effects 
A number of participants expressed enormous relief at being liberated 
from the spiral of increased insulin dosage, accentuation of hunger and 
increased weight often with no obvious improvement in blood glucose 
levels. 
 Unwanted accessory effects 
Metformin is recommended for treatment of overweight or obese 
individuals with T2D, resulting in nausea, abdominal cramps and 
diarrhoea in varying degrees in some recipients, as described by several 
participants. These symptoms overlap with potential side effects of 
incretin analogues, particularly at inception, careful re-balancing of the 
combination of treatments may be essential in some cases. Comments 
from these participants highlighted the value of persevering as these 
symptoms are transitory and much less severe than that experienced 
with metformin. 
 Hypoglycaemia  
Co-prescription of incretin analogues with sulphonylurea or insulin may 
lead to hypoglycaemia. Therefore access to hypoglycaemia awareness 
training and targeted blood glucose monitoring is important to enable 
prompt reduction of concomitant glucose lowering treatments as 
required. However, some participants reported that they had been denied 
blood glucose monitoring equipment by their primary care provider. 
5.4.2 Broader Implications 
Rich data collected from listening to the ‘patient experience’ can improve many 
aspects of care. The open and frank discussions by some participants 
explaining the impact of extreme lethargy when first diagnosed, of real physical 
and social distress precipitated by side effects of metformin, feelings of lack of 
control taking insulin or associated with worsening glycaemia despite increased 
medication are important learning points for any HCP’s involved with people 
living with diabetes. Establishing a dialogue to ensure that changes in 
medication have been effective and well tolerated may improve quality of life 
and compliance whilst also improving outcomes, in many chronic diseases. The 
descriptions of a previous insatiable appetite and a drive to eat anything, to 
satisfy that hunger which made it difficult to implement dietary advice may be 
relevant in the treatment of obesity as well as T2D. 
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In a broader context, perceptions of appropriate portion size and what 
constitutes ‘a proper meal’ are socially and culturally determined and learnt over 
a life-course. Younger HCP’s will need to be aware of the rapid changes that 
have occurred in food and eating patterns during the life of our ageing 
population if they are to support healthy lifestyle interventions. In an increasingly 
culturally and ethnically diverse society, an awareness of the relevance of life-
course experiences when supporting dietary change is applicable across a 
range of healthcare disciplines and conditions. The strategies adopted by the 
participants to overcome difficulties encountered when medication enforced 
changes in long established eating habits may be useful for others.  
5.5 Dissemination and further research 
Interim results of data analysis were presented at Diabetes UK Professional 
Conference (Paisey et al 2012) and Plymouth University Postgraduate Society 
Annual Conference 2012. Insights from the participant responses have been 
shared with colleagues in the research and diabetes clinical teams and 
translated into support for people living with diabetes or other relevant situations 
within the diabetes research team. Articles to present findings are in preparation 
for submission to professional journals. A meeting to thank the participants, 
feedback of results and to discuss future research plans is planned for autumn 
2013. I intend to seek participant permission to use short clips of audiovisual 
recordings describing aspects of living with diabetes and changes in appetite on 
GLP-1 treatment for multi-disciplinary teaching sessions and presentation at 
multi-disciplinary meetings.  
The lived experience gathered by this cohort of individuals with success on 
GLP-1 treatment would be complemented if repeated with people who had not 
responded well to GLP-1 treatment. I am exploring the possibility of extending 
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the research to encompass a broader range of individual response, and of the 
newer longer acting GLP-1 treatments. As GLP-1 treatments are now more 
widely available it would be possible to conduct a larger study if funding and 
ethical permissions were successful. 
An interesting collaboration would be to conduct a similar study in a more 
culturally and ethnically mixed location, this could capture a broader range of 
life-course trajectories and thus identify commonalties and divergence of 
experience. Similar studies could be applicable with other treatments or chronic 
diseases. 
Dietetic support is an important part of standard care when changing or 
escalating treatments. I propose that RCT’s of new T2D medications should 
recognise this important element of care and fund dietetic advice as part of 
research costs. Planned embedded studies employing qualitative interviews or 
focus groups to assess individual participant impact at a selection of 
investigation sites would enhance the evidence and compliment the quantitative 
data. Qualitative studies would be particularly valuable in the trials of GLP-1 
treatment already being conducted in obese individuals without diabetes. 
Obesity surgery is now available following NICE recommendations 2002/041 
(2002) despite poor evidence of long term outcomes (Dixon et al 2012; Søvik et 
al 2010; Buchwald et al 2009). However it is known that levels of GLP-1 are 
rapidly restored following surgery (Mason 2008). A study using GLP-1 treatment 
in conjunction with lifestyle advice counselling and focus groups to explore 
response to resultant appetite reduction could be a very helpful precursor to 
obesity surgery and may help individuals assess they can cope with severe 
portion restriction on their lifestyle prior to surgery. 
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5.6 Final thoughts 
In the past 50 years in industrialised societies the mass production of energy 
dense convenience foods and reduced energy expenditure has resulted in an 
increase in obesity of epidemic proportions in the diverse cultures of the 
Americas, the Far East, Europe, urbanised Africa and the Middle East. The 
difference between maintenance of a healthy body weight or adding 2.7 kg over 
2 years may be just the equivalent of an extra American cookie (60 Kcal) a day 
(Katan and Ludwig 2010). 
For each individual the influences of upbringing, gender role, genetics, work and 
family life are woven into the milieu created by the developed society. The three 
broad themes which emerged from analysis of data discussed in Chapter 4 
demonstrate not only the difficulties encountered by many people living with 
T2D but also that once disturbed the finely balanced human physiological 
responses to food and energy can have far reaching physical, emotional and 
sociological consequences. The contributions from this group of individuals 
shared in the context of research, although specific to their particular life-course 
and diabetes journey, provide insights into a lived experience which may 
resonate with many others. Discussions of living with T2D, experience of 
treatments including GLP-1 as well as difficulties encountered adapting long 
established dietary patterns or previous experience of hunger and lack of 
satiety, may be relevant to others living with T2D, obesity or other chronic 
conditions and healthcare advisors.  
Insights gained from exploring the effects of replacing a satiety hormone 
diminished in T2D and obesity, highlight the complex web of interactions that 
connect the physiological, biochemical and pathological aspects of nutrition to 
the behavioural, cultural and societal experience of food and eating. Crotty 
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(1993, p.109) described these aspects as ‘two cultures’ ‘divided by the act of 
swallowing’ and called for more qualitative research to inform policy and 
practice. It appears that incretin hormones and GLP-1 in particular bridge these 
‘two cultures’, as a pathological reduction or therapeutic enhancement of GLP-1 
has the power to negate or overcome behavioural, cultural and societal 
influences on food and eating. Using qualitative research methodology to 
explore individual response has added to an understanding of how individuals 
navigate a personal path through the myriad of influences which govern 
nutrition. 
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Appendix 1 Participant approach letter with reply 
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Appendix II Participant consent form 
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Appendix III Participant information sheet 
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Appendix IV Schedule for focus group  
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Appendix V Table 1 Association of glycaemia with macrovascular and 
microvascular complications of type 2 diabetes 
 
Percentage risk reduction per 1% improvement in HbA1c  
Any diabetes end point 21% P < 0.0001 
Diabetes deaths  21% P < 0.0001 
Myocardial infarction (fatal or non-fatal) 14% P < 0.0001 
Microvascular complications  37% P < 0.0001 
Amputations  43% P < 0.0001  
Deaths from vascular disease  43% P < 0.0001  
Heart failure 12% P = 0.035* 
Stroke  16% P = 0.021* 
*Improvement in blood pressure had a greater effect for heart failure and stroke  
Table 1 Association of glycaemia with macrovascular and microvascular 
complications of type 2 diabetes (Stratton 2000) 
 
 
  
93 
Appendix VI Anonymised Participant biographies  
(Removed to further protect participant anonymity) 
Appendix VII Table 5 Participant characteristics by group 
All names have been changed to preserve anonymity 
 
Name 
Decade 
of birth 
Living 
arrangements 
T2DM 
in 
years GLP-1 type 
GLP-1 
use in 
months 
Change since starting GLP-1 
Insulin 
use 
weight 
loss Kg 
HbA1c 
drop % 
Group1 
Ruth 50's lives alone 
8 Exenatide 
changed to 
Liraglutide 
22 
no 
plus 
1.55 
1.5 
Adam 40's lives with wife 
11 Exenatide 
changed to 
Liraglutide 
52 
no 9.2 1.1 
Betty 70's lives with carer 16 Exenatide 47 stopped 17.9 3.7 
Bert 30's couple living 
together 
10  Exenatide 52 no 26.75 2.1 
Maud 30's 22 Exenatide 36 stopped 15.4 plus 0.9 
Group2 
Gerald 30's lives with wife 15 Exenatide 48 no 2.2 0.3 
Mavis 30's lives alone 7 Liraglutide 17 reduced 8.8 1.7 
Bob 50's 
lives with wife & 
sons 
7 
Exenatide 48 stopped 23.6 2.4 
Laura 50's 
lives with 
partner 
6 
Liraglutide 16 no plus 1 plus 0.3 
Lionel 30's couple living 
together 
6 Liraglutide 13 reduced 10.25 0.2 
Gwen  1 diet only 
Group3 
Johnny 30's 
lives with 
partner 
11 Exenatide 
changed to 
Liraglutide 
48 reduced 19 2.1 
Cath 40's lives alone 11 Exenatide 24 n/a 4.7 3.1 
Mark 50's lives with wife 
8 Exenatide 
changed to 
Liraglutide 
returned 
Exenatide 
15 reduced 7 0.1 
Linda 60's 
lives with 
daughter & 
partner 
fisherman away 
4 Exenatide 3 no 3 0.4 
Luke 60's lives with wife 6 Exenatide 7 no 7.9 2.8 
Table 5 Participant characteristics by group 
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